

Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons

Amir Qaseem, MD, PhD, MHA; Stephan D. Fihn, MD, MPH; Paul Dallas, MD; Sankey Williams, MD; Douglas K. Owens, MD, MS; and Paul Shekelle, MD, PhD, for the Clinical Guidelines Committee of the American College of Physicians*

Description: The American College of Physicians (ACP) developed this guideline with the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, and Society of Thoracic Surgeons to present the available evidence on the management of stable known or suspected ischemic heart disease.

Methods: Literature on this topic published before November 2011 was identified by using MEDLINE, Embase, Cochrane CENTRAL, PsychINFO, AMED, and SCOPUS. Searches were limited to human studies published in English. This guideline grades the evidence and recommendations according to a translation of the ACCF/AHA

grading system into ACP's clinical practice guidelines grading system.

Recommendations: The guideline includes 48 specific recommendations that address the following issues: patient education, management of proven risk factors (dyslipidemia, hypertension, diabetes, physical activity body weight, and smoking), risk factor reduction strategies of unproven benefit, medical therapy to prevent myocardial infarction and death and to relieve symptoms, alternative therapy, revascularization to improve survival and symptoms, and patient follow-up.

Ann Intern Med. 2012;157:735-743.

For author affiliations, see end of text.

www.annals.org

EXECUTIVE SUMMARY

This guideline presents the available evidence on the management of stable known or suspected ischemic heart disease (IHD). This is the second of 2 guidelines addressing stable IHD; the first guideline addresses the diagnosis of patients with stable IHD (1). Internists and other primary care physicians are the target audiences for this guideline. The target population is all adult patients with stable known or suspected IHD. These recommendations are based on the joint American College of Cardiology Foundation (ACCF), American Heart Association (AHA), American College of Physicians (ACP), American Association for Thoracic Surgery (AATS), Preventive Cardiovascular Nurses Association (PCNA), Society for Cardiovascular Angiography and Interventions (SCAI), and Society of Thoracic Surgeons (STS) guideline for the diagnosis and management of patients with stable IHD published in 2012, which ACP recognized as a scientifically valid, high-quality review of the evidence (2). Full details about methods and evidence are available in the **Appendix** at www.annals.org.

Methods

The databases used for the literature search included MEDLINE, Embase, Cochrane CENTRAL, PsychINFO, AMED, and SCOPUS for studies published up until November 2011. The criteria for search included human participants and English-language articles. For more details on the methods, please refer to the **Appendix** and the ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS guideline for the diagnosis and management of patients with stable IHD (2).

See also:

Print

Related article	729
Editorial comment	749
Summary for Patients	I-48

Web-Only

Appendix: Full Guideline Summary

* This paper, written by Amir Qaseem, MD, PhD, MHA; Stephan D. Fihn, MD, MPH; Paul Dallas, MD; Sankey Williams, MD; Douglas K. Owens, MD, MS; and Paul Shekelle, MD, PhD, was developed for the Clinical Guidelines Committee of the American College of Physicians: Paul Shekelle, MD, PhD (*Chair*); Roger Chou, MD; Molly Cooke, MD; Paul Dallas, MD; Thomas D. Denberg, MD, PhD; Nick Fitterman, MD; Mary Ann Forcica, MD; Robert H. Hopkins Jr., MD; Linda L. Humphrey, MD, MPH; Tanveer P. Mir, MD; Holger J. Schünemann, MD, PhD; Donna E. Sweet, MD; and Timothy Wilt, MD, MPH. Approved by the ACP Board of Regents on 16 April 2012.

Table 1. The American College of Physicians Guideline Grading System*

Quality of Evidence	Strength of Recommendation	
	Benefits Clearly Outweigh Risks and Burden or Risks and Burden Clearly Outweigh Benefits	Benefits Finely Balanced With Risks and Burden
High	Strong	Weak
Moderate	Strong	Weak
Low	Strong	Weak
Insufficient evidence to determine net benefits or risks		

* Adopted from the classification developed by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) workgroup.

Because this document is based on the joint guideline, ACP translated the ACCF/AHA evidence and recommendation grades into ACP’s guideline grading system (Tables 1 and 2) (3). We included only class I and class III statements from the joint guideline because the evidence very clearly demonstrates the tradeoff between benefits and harms (Table 2). For details on other recommendations, please refer to the ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS guideline for the diagnosis and management of patients with stable IHD (2).

The objective of this guideline is to synthesize the evidence for the following key questions:

- 1: What should be the approach to modifying cardiovascular risk factors to reduce the mortality and morbidity associated with stable IHD?
- 2: What is the role of coronary revascularization in reducing mortality and morbidity associated with stable IHD?
- 3: How should chronic anginal symptoms be managed with medications?

General Approach to Treatment

The goals of treating patients with stable IHD are to 1) prevent premature cardiovascular death and complications of stable IHD, including nonfatal acute myocardial

infarction (MI) and heart failure, and 2) maintain or restore a quality of life that is satisfactory to the patient while eliminating avoidable adverse effects of tests and treatments, preventing hospital admissions, and eliminating unnecessary tests and treatments. This approach acknowledges that certain interventions are primarily aimed at improving survival, whereas others are undertaken largely to reduce symptoms, although under some circumstances, a treatment may be provided to achieve both aims simultaneously. The evolving approach to management of patients with stable IHD entails a “package” of therapies that are appropriate for most patients who do not have specific contraindications. These include lifestyle changes and specific medications, which together are called *guideline-directed medical therapy* and are prescribed regardless of decisions regarding revascularization (Figure 1).


The initial approach to all patients should be focused on eliminating unhealthy behaviors, such as smoking, and effectively promoting lifestyle changes that reduce cardiovascular risk, such as increasing weight loss, physical activity, and adopting a healthy diet. In addition, for most patients, an evidence-based set of pharmacologic interventions is indicated to reduce the risk for future events. The presumed mechanism by which these interventions are effective is by stabilizing the coronary plaque to prevent rupture and thrombosis (4). These include antiplatelet agents (5); lipid-lowering agents, in particular hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) (6–13); and β -blockers (14, 15). Angiotensin-converting enzyme (ACE) inhibitors are indicated in many patients with stable IHD, especially those with diabetes or left ventricular (LV) dysfunction (16–18). Similarly, although tight glycemic control has not been shown to reduce the risk for macrovascular complications in patients with type 2 diabetes, weight loss, aerobic exercise, an AHA Step II diet, and ACE inhibitors in those with proteinuria can all improve patients’ risks for microvascular complications and, potentially, cardiac events. Revascularization improves survival in specific subgroups of patients, whereas it should be undertaken to relieve symptoms in others.

Table 2. Comparison of Grading Systems From the ACP and ACCF/AHA

Description	ACP’s Grading System		ACCF/AHA’s Grading System (Size vs. Certainty)		
	Grade (For or Against Intervention)		Grade	Class	
	Recommendation	Evidence		For	Against
Benefits clearly outweigh risks and burden or vice versa	Strong	High-quality	A	I	III
Benefits clearly outweigh risks and burden or vice versa	Strong	Moderate-quality	B	I	III
Benefits clearly outweigh risks and burden or vice versa	Strong	Low-quality	C	I	III
Benefits closely balanced with risks and burden	Weak	High-quality	A	IIa, IIb	NER
Benefits closely balanced with risks and burden	Weak	Moderate-quality	B	IIa, IIb	NER
Uncertainty, benefits may be closely balanced with risks and burden	Weak	Low-quality	C	IIa, IIb	NER

ACCF = American College of Cardiology Foundation; ACP = American College of Physicians; AHA = American Heart Association; NER = no equivalent rating.

Figure 1. Guideline-directed medical therapy for patients with stable ischemic heart disease.



ACCF = American College of Cardiology Foundation; ACEI = angiotensin-converting enzyme inhibitor; AHA = American Heart Association; ARB = angiotensin-receptor blocker; ASA = aspirin; ATP III = Adult Treatment Panel III; BP = blood pressure; CCB = calcium-channel blocker; CKD = chronic kidney disease; JNC VII = Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LV = left ventricular; MI = myocardial infarction; NHLBI = National Heart, Lung, and Blood Institute; NTG = nitroglycerin.

* The use of bile acid sequestrant is relatively contraindicated when triglyceride levels are 200 mg/dL or greater and is contraindicated when triglyceride levels are 500 mg/dL or greater.

† Dietary supplement niacin must not be used as a substitute for prescription niacin.

Recommendations

Patient Education

Recommendation 1: The organizations recommend that patients with stable IHD should have an individualized education plan to optimize care and promote wellness, including:

A. Education on the importance of medication adherence for managing symptoms and reducing disease progression (Grade: strong recommendation; low-quality evidence).

B. An explanation of medication management and cardiovascular risk reduction strategies in a manner that respects the patient’s level of understanding, reading comprehension, and ethnicity (Grade: strong recommendation; moderate-quality evidence).

C. A comprehensive review of all therapeutic options (Grade: strong recommendation; moderate-quality evidence).

D. A description of appropriate levels of exercise with encouragement to maintain recommended levels of daily physical activity (Grade: strong recommendation; low-quality evidence).

E. Introduction to self-monitoring skills (Grade: strong recommendation; low-quality evidence).

F. Information on how to recognize worsening cardiovascular symptoms and take appropriate action (Grade: strong recommendation, low-quality evidence).

Recommendation 2: The organizations recommend that patients with stable IHD should be educated regarding the following lifestyle elements that may influence prognosis (Grade: strong recommendation; low-quality evidence):

A. Weight control and maintenance of a body mass index of 18.5 to 24.9 kg/m² and waist circumference less than 40 inches for men and less than 35 inches for women (less for certain racial groups).

B. Lipid management.

C. Blood pressure control.

D. Smoking cessation and avoidance of exposure to second-hand smoke.

E. Individualized medical, nutrition, and lifestyle education for patients with diabetes mellitus to supplement diabetes treatment goals and education.

Risk Factor Modification

Lipid Management. Recommendation 3: The organizations recommend lifestyle modifications for lipid management in all patients with stable IHD, including daily physical activity and weight management (Grade: strong recommendation; moderate-quality evidence).

Recommendation 4: The organizations recommend dietary therapy for all patients, which should include reduced intake of saturated fats (to <7% of total calories), trans-fatty acids (to <1% of total calories), and cholesterol (to <200 mg per day) (Grade: strong recommendation; moderate-quality evidence).

Recommendation 5: The organizations recommend that in addition to therapeutic lifestyle changes, a moderate or high dose of a statin therapy should be prescribed in the absence of contraindications or documented adverse effects. (Grade: strong recommendation; high-quality evidence).

Hypertension. Recommendation 6: The organizations recommend that patients with stable IHD who have high blood pressure should be counseled regarding the need for lifestyle modifications, including maintenance of recommended weight; increased physical activity; moderation of alcohol consumption; limitation of dietary sodium; and emphasis on increased consumption of fresh fruits, vegetables, and low-fat dairy products (Grade: strong recommendation; moderate-quality evidence).

Recommendation 7: The organizations recommend that patients with stable IHD with blood pressure of 140/90 mm Hg or higher should be treated with antihypertensive drug therapy in addition to following a trial of lifestyle modifica-

tions (Grade: strong recommendation; high-quality evidence). The specific medications used for treatment of high blood pressure should be based on specific patient characteristics, and may include ACE inhibitors and/or β -blockers, with addition of other drugs, such as thiazide diuretics or calcium-channel blockers, if needed to achieve a goal blood pressure of less than 140/90 mm Hg (Grade: strong recommendation; moderate-quality evidence).

Diabetes. Recommendation 8: The organizations recommend that therapy with rosiglitazone should not be initiated in diabetic patients with stable IHD (Grade: strong recommendation; low-quality evidence).

Physical Activity. Recommendation 9: The organizations recommend risk assessment with a physical activity history to guide prognosis and prescription for all patients. An exercise test should be obtained when clinically indicated (Grade: strong recommendation; moderate-quality evidence). As indicated, based on this assessment, patients with stable IHD should be encouraged to engage in 30 to 60 minutes of moderate-intensity aerobic activity, such as brisk walking, at least 5 days and preferably 7 days of the week, supplemented by an increase in daily activities (such as walking breaks at work, gardening, or household work) to improve cardiorespiratory fitness and motivate patients of the least fit, least active high-risk cohort (bottom 20%) (Grade: strong recommendation; moderate-quality evidence). Medically supervised programs (cardiac rehabilitation) and physician-directed, home-based programs are recommended for at-risk patients at first diagnosis (Grade: strong recommendation; high-quality evidence).

Weight Management. Recommendation 10: The organizations recommend assessing body mass index and/or waist circumference at every visit and consistently encouraging weight maintenance/reduction through an appropriate balance of lifestyle physical activity, structured exercise, caloric intake, and formal behavioral programs when indicated to maintain/achieve a body mass index between 18.5 and 24.9 kg/m², and waist circumference less than 40 inches in men and less than 35 inches in women (less for certain racial groups) (Grade: strong recommendation; moderate-quality evidence). The initial goal of weight loss therapy should be to reduce body weight by approximately 5% to 10% from baseline. With success, further weight loss can be attempted if indicated (Grade: strong recommendation; low-quality evidence).

Smoking Cessation. Recommendation 11: The organizations recommend that smoking cessation and avoidance of exposure to environmental tobacco smoke at work and at home should be encouraged for all patients with stable IHD. A stepwise strategy for smoking cessation (Ask, Advise, Assess, Assist, Arrange), follow-up, referral to special programs, and/or pharmacotherapy are recommended (Grade: strong recommendation; moderate-quality evidence).

Risk Factor Reduction Strategies of Unproven Benefits. Recommendation 12: The organizations recommend that estrogen therapy should not be initiated in postmenopausal

women with stable IHD with the intent of reducing cardiovascular risk or improving clinical outcomes (Grade: strong recommendation; high-quality evidence).

Recommendation 13: The organizations recommend that vitamin C, vitamin E, and β -carotene supplementation should not be used with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with stable IHD (Grade: strong recommendation; high-quality evidence).

Recommendation 14: The organizations recommend that treatment of elevated homocysteine with folate and/or vitamins B₆ and B₁₂ should not be used with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with stable IHD (Grade: strong recommendation; high-quality evidence).

Recommendation 15: The organizations recommend that chelation therapy should not be used with the intent of improving symptoms or reducing cardiovascular risk in patients with stable IHD (Grade: strong recommendation; low-quality evidence).

Recommendation 16: The organizations recommend that treatment with garlic, coenzyme Q₁₀, selenium, or chromium should not be used with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with stable IHD (Grade: strong recommendation; low-quality evidence).

Medical Therapy to Prevent MI and Death in Patients With Stable IHD

Recommendation 17: The organizations recommend that aspirin, 75 to 162 mg daily, should be continued indefinitely in the absence of contraindications in patients with stable IHD (Grade: strong recommendation; high-quality evidence).

Recommendation 18: The organizations recommend treatment with clopidogrel as a reasonable option when aspirin is contraindicated in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Recommendation 19: The organizations recommend that dipyridamole should not be used as antiplatelet therapy for patients with stable IHD (Grade: strong recommendation; low-quality evidence).

Recommendation 20: The organizations recommend that β -blocker therapy should be initiated and continued for 3 years in all patients with normal LV function following MI or acute coronary syndromes (Grade: strong recommendation; moderate-quality evidence).

Recommendation 21: The organizations recommend that metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction $\leq 40\%$) with heart failure or prior MI, unless contraindicated (Grade: strong recommendation; high-quality evidence).

Recommendation 22: The organizations recommend that ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction $\leq 40\%$), and/or chronic kidney disease, unless contraindicated (Grade: strong recommendation; high-quality evidence).

Recommendation 23: The organizations recommend angiotensin-receptor blockers for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors (Grade: strong recommendation; high-quality evidence).

Recommendation 24: The organizations recommend an annual influenza vaccine for patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Medical Therapy for Relief of Symptoms in Patients With Stable IHD

Recommendation 25: The organizations recommend that β -blockers should be prescribed as initial therapy for relief of symptoms in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Recommendation 26: The organizations recommend that calcium-channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β -blockers are contraindicated or cause unacceptable side effects in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Recommendation 27: The organizations recommend that calcium-channel blockers or long-acting nitrates, in combination with β -blockers, should be prescribed for relief of symptoms when initial treatment with β -blockers is unsuccessful in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Recommendation 28: The organizations recommend that sublingual nitroglycerin or nitroglycerin spray should be used for immediate relief of angina in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Alternative Therapy for Relief of Symptoms in Patients With Stable IHD

Recommendation 29: The organizations recommend that acupuncture should not be used for the purpose of improving symptoms or reducing cardiovascular risk in stable IHD patients (Grade: strong recommendation; low-quality evidence).

Revascularization

Recommendation 30: The organizations recommend that a shared decision-making approach should be utilized when making decisions about revascularization in patients with unprotected left main or complex coronary artery disease and should include a cardiac surgeon, an interventional cardiologist, and the patient (Grade: strong recommendation; low-quality evidence).

Revascularization to Improve Survival. **Recommendation 31:** The organizations recommend coronary artery bypass graft to improve survival for patients with significant ($\geq 50\%$ diameter stenosis) left main coronary artery stenosis (Grade: strong recommendation; moderate-quality evidence).

Recommendation 32: The organizations recommend that percutaneous coronary intervention to improve survival should

not be performed in stable patients with significant ($\geq 50\%$ diameter stenosis) unprotected left main coronary artery disease who have unfavorable anatomy for percutaneous coronary intervention and who are good candidates for coronary artery bypass graft (Grade: strong recommendation; moderate-quality evidence).

Recommendation 33: The organizations recommend the use of coronary artery bypass graft to improve survival in patients with significant ($\geq 70\%$ diameter) stenoses in 3 major coronary arteries (with or without involvement of the proximal left anterior descending artery) or in the proximal left anterior descending artery plus 1 other major coronary artery (Grade: strong recommendation; moderate-quality evidence).

Recommendation 34: The organizations recommend the use of coronary artery bypass graft or percutaneous coronary

intervention to improve survival in survivors of sudden cardiac death with presumed ischemia-mediated ventricular tachycardia caused by significant ($\geq 70\%$ diameter) stenosis in a major coronary artery (Grade: strong recommendation; moderate-quality evidence for coronary artery bypass graft, low-quality evidence for percutaneous coronary intervention).

Recommendation 35: The organizations recommend that coronary artery bypass graft or percutaneous coronary intervention should not be performed with the primary or sole intent to improve survival in patients with stable IHD with 1 or more coronary stenoses that are not anatomically or functionally significant (for example, $< 70\%$ diameter non-left main coronary artery stenosis, fractional flow reserve > 0.80 , no or only mild ischemia on noninvasive testing), involve only the left circumflex or right coronary artery, or subtend only a small area of viable myocardium (Grade: strong recommendation; moderate-quality evidence).

Revascularization to Improve Symptoms. **Recommendation 36:** The organizations recommend the use coronary artery bypass graft or percutaneous coronary intervention to improve symptoms in patients with 1 or more significant ($\geq 70\%$ diameter) coronary artery stenoses amenable to revascularization and unacceptable angina despite guideline-directed medical therapy (Grade: strong recommendation; high-quality evidence).

Recommendation 37: The organizations recommend that the use coronary artery bypass graft or percutaneous coronary intervention to improve symptoms should not be performed in patients who do not meet anatomical ($\geq 50\%$ diameter left main or $\geq 70\%$ non-left main stenosis diameter) or physiologic (for example, abnormal fractional flow reserve) criteria for revascularization (Grade: strong recommendation; low-quality evidence).


Recommendation 38: The organizations recommend that percutaneous coronary intervention with coronary stenting (bare-metal stent or drug-eluting stent) should not be performed if the patient is not likely to be able to tolerate and comply with dual antiplatelet therapy for the appropriate duration of treatment based on the type of stent implanted (Grade: strong recommendation; moderate-quality evidence).

Patient Follow-up

Recommendation 39: The organizations recommend that patients with stable IHD should receive periodic follow-up at least annually that includes all of the following (Grade: strong recommendation; low-quality evidence):

- A. Assessment of symptoms and clinical function.
- B. Surveillance for complications of stable IHD, including heart failure and arrhythmias.
- C. Monitoring of cardiac risk factors.
- D. Assessment of the adequacy of and adherence to recommended lifestyle changes and medical therapy.

Recommendation 40: The organizations recommend assessment of LV ejection fraction and segmental wall motion by



echocardiography or radionuclide imaging in patients with new or worsening heart failure or evidence of intervening MI by history or electrocardiogram (Grade: strong recommendation; low-quality evidence).

Recommendation 41: The organizations recommend that measurement of LV function with a technology such as echocardiography or radionuclide imaging should not be used for routine periodic reassessment of patients who have not had a change in clinical status or who are at low risk of adverse cardiovascular events (Grade: strong recommendation; low-quality evidence).

Recommendation 42: The organizations recommend standard exercise electrocardiogram in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina and who have a) at least moderate physical functioning and no disabling comorbidity and b) an interpretable electrocardiogram (Grade: strong recommendation; moderate-quality evidence).

Recommendation 43: The organizations recommend exercise with radionuclide myocardial perfusion imaging or echocardiography in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina, and who have a) at least moderate physical functioning or no disabling comorbidity but b) an uninterpretable electrocardiogram (Grade: strong recommendation; moderate-quality evidence).


Recommendation 44: The organizations recommend that pharmacologic stress imaging with radionuclide myocardial perfusion imaging, echocardiography, or cardiac magnetic resonance should not be used in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina and who are capable of at least moderate physical functioning or have no disabling comorbidity (Grade: strong recommendation; low-quality evidence).

Recommendation 45: The organizations recommend pharmacologic stress imaging using radionuclide myocardial perfusion or echocardiography in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina and who are incapable of at least moderate physical functioning or have disabling comorbidity (Grade: strong recommendation; moderate-quality evidence).

Recommendation 46: The organizations recommend that standard exercise electrocardiogram testing should not be performed in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina and who a) are incapable of at least moderate physical functioning or have disabling comorbidity or b) have an uninterpretable electrocardiogram (Grade: strong recommendation; low-quality evidence).

Recommendation 47: The organizations recommend that coronary/cardiac computed tomography angiography should not be performed for assessment of native coronary arteries with known moderate or severe calcification or of coronary stents less than 3 mm in diameter in patients with known

Figure 3. Revascularization to improve symptoms of patients with stable ischemic heart disease.



CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention.

stable IHD who have new or worsening symptoms not consistent with unstable angina, irrespective of ability to exercise (Grade: strong recommendation; moderate-quality evidence).

Recommendation 48: The organizations recommend that radionuclide myocardial perfusion imaging, echocardiography, or cardiac magnetic resonance, with either exercise or pharmacologic stress or coronary/cardiac computed tomography angiography, should not be used for follow-up assessment in patients with stable IHD, if performed more frequently than at a) 5-year intervals after coronary artery bypass graft or b) 2-year intervals after percutaneous coronary intervention (Grade: strong recommendation; low-quality evidence).

Summary

The goals of managing patients with stable IHD include reducing premature cardiovascular death and non-fatal MI while maintaining a level of activity, functional capacity, and quality of life that is satisfactory to the patient. See **Figures 1 to 3** for algorithms on medical care, revascularization to improve survival, and revascularization to improve symptoms.

Because of the variation in symptoms and clinical characteristics among patients, as well as their unique perceptions, expectations, and preferences, there is clearly no single correct approach to any given set of clinical circumstances. Patient education regarding various therapeutic options, appropriate levels of exercise, diet and weight control, and the importance of various clinical manifestations play a key role in achieving the treatment goal. Lifestyle modifications are also critical for all patients with stable IHD to control weight and high blood pressure and manage diabetes. Various pharmacologic approaches can be used to prevent MI or death in patients with stable IHD, including daily aspirin, β -blockers, ACE inhibitors or angiotensin-receptor blockers, and influenza vaccination. For patients with symptoms, various pharmacologic options are available to relieve symptoms. Although there is limited evidence of the efficacy of specific strategies for the follow-up of patients with stable IHD, there is emerging consensus that patients with a variety of chronic illnesses have improved outcomes when they receive coordinated care. Patients with stable IHD require regular monitoring to assess changes in their status, their response, and adherence to guideline-directed medical therapy.

From the American College of Physicians and University of Pennsylvania, Philadelphia, Pennsylvania; Department of Veterans Affairs, Seattle, Washington; Veterans Affairs Palo Alto Health Care System and Stanford University, Stanford, California; Virginia Tech Carilion School of Medicine, Roanoke, Virginia; and West Los Angeles Veterans Affairs Medical Center, Los Angeles, California.

Note: Clinical practice guidelines are “guides” only and may not apply to all patients and all clinical situations. Thus, they are not intended to override clinicians’ judgment. All ACP clinical practice guidelines are considered automatically withdrawn or invalid 5 years after publication or once an update has been issued.

Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations.

Financial Support: Financial support for the development of this guideline comes exclusively from the ACP operating budget.

Potential Conflicts of Interest: Any financial and nonfinancial conflicts of interest of the group members were declared, discussed, and resolved according to ACP’s conflicts of interest policy. A record of conflicts of interest is kept for each Clinical Guidelines Committee meeting and conference call and can be viewed at www.acponline.org/clinical_information/guidelines/guidelines/conflicts_cg.c.htm. Author and peer reviewer disclosure information for the multisocietal stable IHD guideline, on which these guidelines are based, may be found in the published multisocietal document (2). Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-1770.

Requests for Single Reprints: Amir Qaseem, MD, PhD, MHA, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106; e-mail, aqaseem@acponline.org.

Current author addresses and author contributions are available at www.annals.org.

References

1. Qaseem A, Fihn SD, Williams S, Dallas P, Owens DK, Shekelle P; for the Clinical Guidelines Committee of the American College of Physicians. Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med.* 2012;157:729-34.
2. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas P, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2012. [Forthcoming].
3. Qaseem A, Snow V, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. *Ann Intern Med.* 2010;153:194-9. [PMID: 20679562]
4. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al; AHA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol.* 2006;47:2130-9. [PMID: 16697342]
5. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med.* 2006;354:1706-17. [PMID: 16531616]
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994;344:1383-9. [PMID: 7968073]
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med.* 1996;335:1001-9. [PMID: 8801446]
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med.* 1998;339:1349-57. [PMID: 9841303]
9. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary

artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med.* 1999;341:70-6. [PMID: 10395630]

10. **Heart Protection Study Collaborative Group.** MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet.* 2002;360:7-22. [PMID: 12114036]

11. **Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators.** C-reactive protein levels and outcomes after statin therapy. *N Engl J Med.* 2005;352:20-8. [PMID: 15635109]

12. **LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators.** Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med.* 2005;352:1425-35. [PMID: 15755765]

13. **Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al.** Effectiveness of statin therapy in adults with coronary heart disease. *Arch Intern Med.* 2004;164:1427-36. [PMID: 15249352]

14. **Gottlieb SS, McCarter RJ, Vogel RA.** Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med.* 1998;339:489-97. [PMID: 9709041]

15. **Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH.** Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. *Arch Intern Med.* 1993;153:578-81. [PMID: 8439221]

16. **Libby P, Aikawa M.** Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. *Nat Med.* 2002;8:1257-62. [PMID: 12411953]

17. **Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.** Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med.* 2000;342:145-53. [PMID: 10639539]

18. **Fox KM; EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.** Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet.* 2003;362:782-8. [PMID: 13678872]

MANUSCRIPT PROCESSING AND TURNAROUND

Annals sends about half of submitted manuscripts for peer review and publishes about 10% of submitted material. The 2011 processing and notification turnaround time for manuscripts that were rejected without external peer review was within 1 week for more than 95% of submitted manuscripts. The processing and notification turnaround time for manuscripts that were received and rejected after external peer review was within 4 weeks for 64% and within 8 weeks for 98%.

APPENDIX: MANAGEMENT OF STABLE ISCHEMIC HEART DISEASE: A CLINICAL PRACTICE GUIDELINE SUMMARY FROM THE AMERICAN COLLEGE OF PHYSICIANS/ AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION/ AMERICAN HEART ASSOCIATION/AMERICAN ASSOCIATION FOR THORACIC SURGERY/PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION/ SOCIETY OF THORACIC SURGEONS

Ischemic heart disease (IHD) is a major public health issue that affects an estimated 1 in 3 adults in the United States (19). It is the single leading cause of death and is responsible for 1 of every 4 deaths. Approximately 71 million Americans have some form of cardiovascular disease, including more than 13 million with coronary artery disease (CAD) and more than 9 million with angina pectoris (19). The prevalence of IHD increases with age; approximately 23% of men and 15% of women in the United States have IHD. The costs of caring for patients with IHD are enormous: an estimated \$156 billion in the United States for both direct and indirect costs in 2008 (20). These costs include hospitalizations, invasive procedures, emergency department visits, and long-term care.

The purpose of this guideline is to present the available evidence on the management of stable known or suspected IHD in adult patients. This is the second of 2 guidelines addressing stable IHD; the first guideline addressed the diagnosis of patients with stable IHD (21). The target audience for this guideline is all internists and other primary care physicians. The target population is all adult patients with stable known or suspected IHD. These recommendations are based on the joint guideline on the diagnosis and management of patients with stable IHD from the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), American College of Physicians (ACP), American Association for Thoracic Surgery (AATS), Preventive Cardiovascular Nurses Association (PCNA), Society for Cardiovascular Angiography and Interventions (SCAI), and Society of Thoracic Surgeons (STS) published in 2012, which ACP recognized as a scientifically valid, high-quality review of the evidence (22).

Methods

The databases used for the literature search included MEDLINE, Embase, Cochrane CENTRAL, PsychINFO, AMED, and SCOPUS for studies published up until November 2011. The criteria for search included human participants and English-language articles. For more details on the methods, please refer to the ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS guideline for the diagnosis and management of patients with stable IHD (22).

ACP guideline recommendations are based on evidence from systematic reviews of high-quality evidence (several well-designed randomized, controlled trials) and meta-analyses where appropriate. Because this document is based on the joint ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS guideline, ACP translated the ACCF/AHA evidence and recommendation grading system into ACP's guideline grading system (Tables 1 and 2,

in Executive Summary). We included only class I and class III statements from the ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS guideline because the evidence very clearly demonstrated that benefits outweigh harms or vice versa (Table 2, in Executive Summary). For details on other recommendations, please refer to the ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS guideline for the diagnosis and management of patients with stable IHD (22).

The objective of this guideline is to synthesize the evidence for the following key questions:

1: What should be the approach to modifying cardiovascular risk factors to reduce the mortality and morbidity associated with stable IHD?

2: What is the role of coronary revascularization in reducing mortality and morbidity associated with stable IHD?

3: How should chronic anginal symptoms be managed with medications?

General Approach to Treatment

The goals of treating patients with stable IHD are to 1) prevent premature cardiovascular death and complications of stable IHD, including nonfatal acute myocardial infarction (MI) and heart failure, and 2) maintain or restore a quality of life that is satisfactory to the patient while eliminating avoidable adverse effects of tests and treatments, preventing hospital admissions, and eliminating unnecessary tests and treatments. This approach acknowledges that certain interventions are primarily aimed at improving survival, whereas others are undertaken largely to reduce symptoms; under some circumstances, however, a treatment may be provided to achieve both aims simultaneously. The evolving approach to management of patients with stable IHD entails a "package" of therapies that are appropriate for most patients who do not have specific contraindications. These include lifestyle changes and specific medications that together are called *guideline-directed medical therapy* (GDMT) and are prescribed irrespective of decisions regarding revascularization (Figure 1, in Executive Summary).

The initial approach to all patients should be focused on eliminating unhealthy behaviors, such as smoking, and effectively promoting lifestyle changes that reduce cardiovascular risk, such as increasing weight loss, physical activity, and adopting a healthy diet. In addition, for most patients, an evidence-based set of pharmacologic interventions is indicated to reduce the risk for future events. The presumed mechanism by which these interventions are effective is by stabilizing the coronary plaque to prevent rupture and thrombosis (23). These include antiplatelet agents (24); lipid-lowering agents, in particular hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) (25–32); and β -blockers (33, 34). Angiotensin-converting enzyme (ACE) inhibitors are indicated in many patients with stable IHD, especially those with diabetes or left ventricular (LV) dysfunction (35–37). Similarly, although tight glycemic control has not been shown to reduce the risk for macrovascular complications in patients with type 2 diabetes, weight loss, aerobic exercise, an AHA Step II diet, and ACE inhibitors in those with proteinuria can all

improve patients' risks for microvascular complications and, potentially, cardiac events. Revascularization improves survival in specific subgroups of patients, whereas it should be undertaken to relieve symptoms in others.

Patient Education for Persons With Stable IHD

Patients with stable IHD usually have multiple risk factors for heart disease, vascular disease, and stroke (38, 39). These risk factors include hypertension, cigarette smoking, dyslipidemia, diabetes, obesity, physical inactivity, and psychological states (such as depression) that contribute to higher rates of morbidity and mortality (38, 39). The approach to the management for all risk factors requires partnerships among the health care team, the patient and family, and the community. The goal of this partnership is to assure an effective exchange of information, sharing of concerns, and improved understanding of treatments with the aim of improving quality-of-life and health outcomes. Effective patient education and counseling as well as active patient involvement are crucial (40). Successful clinical management depends on patients' understanding of their condition, their ability to safely adhere to complex medical therapies, and their willingness to communicate on a regular basis with their health care team. Effectively communicating with patients about their condition; management of and adherence to recommended lifestyle changes and medications, diagnostic tests, and procedures; and the necessity of reporting adverse effects is essential (23, 41). It is also important to integrate patients' individual cognitive, behavioral, and sociodemographic characteristics into the communication and to incorporate them into the communication process.

Evidence supports the use of an individualized plan of education that addresses various therapeutic options (23, 40–45), diet (23, 46–49), physical activity (23, 50–52), importance of weight control (23, 41, 53–57), blood pressure control (49, 58), smoking cessation (23, 59, 60), and medication adherence (61–63).

Risk Factor Modification

Lipid Management

Serum cholesterol is a well-established independent risk factor for coronary heart disease (64–67), and this also holds true in patients with stable IHD (68–70). Effective dietary approaches to lowering low-density lipoprotein (LDL) cholesterol include replacing saturated and trans-fatty acids with dietary carbohydrates or unsaturated fatty acids, as well as reducing dietary cholesterol (71–74). Evidence suggests decreasing intake of saturated fats to less than 7% of total calories, with trans-fatty acids, and total cholesterol to less than 200 mg/d (71–74). In addition, regular physical activity is also a key component of therapeutic lifestyle modification because it facilitates weight loss and has other beneficial effects on the lipid profile (75–77).

In addition to dietary modification, evidence has established the efficacy of statins in the primary and secondary prevention of coronary events (15–17, 31, 78–83). Each 40-mg/dL reduction in LDL cholesterol was associated with a 12% reduction in all-cause mortality and 19% reduction in coronary mortality, with corresponding reductions in MI, need for coronary revascularization, and fatal or nonfatal strokes (48). Data support intensive

LDL cholesterol-lowering with statins in patients with stable IHD (31, 78, 79), including those who have LDL cholesterol levels less than 130 mg/dL (84). However, clinical trials to date have neither established an absolute or optimal threshold of benefit with regard to reduction in LDL cholesterol levels nor provided evidence that a particular statin drug in a particular dosage is preferred. An update of the Adult Treatment Panel III (ATP III) report recommends treatment to an LDL cholesterol level less than 100 mg/dL in patients with established coronary disease or other high-risk features and an LDL cholesterol goal of less than 70 mg/dL as a therapeutic option in patients at very high risk (85). Factors that identify patients at very high risk include the presence of established coronary vascular disease plus 1) multiple major risk factors, especially diabetes; 2) severe and poorly controlled risk factors, especially continued tobacco use; and 3) multiple risk factors for the metabolic syndrome.

When statins are insufficiently effective, not tolerated, or contraindicated or cause adverse effects, other lipid-lowering agents can be substituted or added. Evidence from randomized, controlled trials shows that treatment with cholesterol-binding resins (such as cholestyramine) and niacin improves survival compared with placebo. Less evidence favors fibric acid derivatives (such as gemfibrozil) for patients with hypercholesterolemia. Evidence from observational studies and treatment trials shows benefits of consumption of omega-3 fatty acids in reducing cardiovascular risk (86–88). Ezetimibe decreases cholesterol but has not been shown to improve clinical outcomes.

A secondary target of therapy introduced by the ATP III is non-high-density lipoprotein (HDL) cholesterol in patients with elevated triglyceride levels (46). Non-HDL cholesterol is defined as the difference between total cholesterol and HDL cholesterol. It includes all cholesterol and lipoprotein particles that are considered atherogenic, including LDL, lipoprotein(a), intermediate-density lipoprotein, and very-low-density lipoprotein, and is a predictor of cardiovascular death (89). Because statins reduce LDL cholesterol and non-HDL cholesterol to a similar extent, the relative benefits of decreasing these 2 lipid measures cannot be distinguished on the basis of recent clinical trials.

Hypertension

In a meta-analysis of prospective studies involving nearly 1 million adults without pre-existing vascular disease, the risk for vascular death increased linearly over the blood pressure range of 115/75 to 185/115 mm Hg, without a threshold effect (90). In general, the evidence supports a target blood pressure of 140/90 mm Hg or less in patients with stable IHD (91–97).

The first step in managing hypertension includes lifestyle modification. This includes maintenance of an appropriate body weight with a body mass index (BMI) less than 25 kg/m². However, a weight loss of 10 kg is also associated with a decrease in blood pressure of 5 to 20 mm Hg (98–102). In addition, dietary habits, such as consumption of fruits, vegetables, and low-fat dairy products (103, 104); reduction of sodium intake (98, 99, 104–106); regular physical activity (107); and moderation of

alcohol consumption (108), are also related to lower blood pressure.

In patients for whom lifestyle modification measures do not sufficiently reduce blood pressure, therapy with medications is warranted. Several treatment trials have definitively demonstrated a beneficial effect of antihypertensive drug therapy in reducing cardiovascular risk (92, 96, 109, 110). However, the appropriate blood pressure threshold for initiating medical therapy in patients with stable IHD remains controversial. Evidence from randomized, controlled trials has demonstrated a benefit from antihypertensive therapy in patients with a diastolic blood pressure greater than 90 mm Hg (74) and also in patients with isolated systolic hypertension and a systolic blood pressure greater than 160 mm Hg (92, 109, 110). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) recommends a target blood pressure of less than 140/90 mm Hg in patients with uncomplicated hypertension (49). However, caution with regard to overly aggressive lowering of blood pressure in patients with stable IHD is warranted because excessive reduction in diastolic pressure has not conclusively been shown to improve outcomes and has been associated with an increase in mortality, potentially related to reduced coronary perfusion (111–113).

Clinical trials have shown no differences among available antihypertensive medications in preventing coronary events (114, 115). The choice of therapy is guided by an individualized assessment of patients who have stable IHD and the indications for specific classes of drugs. Angiotensin-converting enzyme inhibitors improve outcomes in most patients with coronary disease, especially those with a history of MI, LV dysfunction and heart failure, or chronic kidney disease or diabetes (36, 37, 116–121). Angiotensin-receptor blockers (ARBs) are beneficial in the same spectrum of patients and are recommended for patients who are unable to tolerate ACE inhibitors (122–125). β -Blockers are recommended for patients with angina pectoris, a history of MI, or LV dysfunction (126–130). Calcium antagonists are useful in the treatment of angina. Many patients with stable IHD will require a combination of drugs, including a diuretic, to achieve optimal blood pressure control.

Diabetes

Diabetes is an important independent risk factor for cardiovascular disease. Type 1 diabetes is associated with at least a 10-fold increase in cardiovascular events (131, 132), and type 2 diabetes is associated with a 2 to 6 times increased risk for death from cardiovascular events compared with persons without diabetes (133–135). Diabetes is also associated with poor outcomes in patients with stable IHD (136).

Good evidence supports the benefits of glycemic control in reducing microvascular complications of diabetes (137, 138). However, the efficacy of intensive diabetes therapy in reducing cardiovascular disease is not established (137, 139–141). The Diabetes Control and Complications Trial (DCCT), which studied patients with type 1 diabetes, showed that fewer cardiovascular events occurred in the patient group exposed to intensive

therapy (average hemoglobin A_{1c} achieved, 7.4%) compared with conventional therapy (average hemoglobin A_{1c} achieved, 9.1%) but the difference between groups was not statistically significant (137). The UKPDS (United Kingdom Prospective Diabetes Study), which studied patients with type 2 diabetes (142), and the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation) trial (140) provided similar results, with no statistically significant effect on cardiovascular events with intensive glycemic control.

The most appropriate target level for hemoglobin A_{1c} in patients with diabetes has not been definitively established by clinical trials. According to the ACP recommendations, the goal for the hemoglobin A_{1c} level should be based on individualized assessment of risk for complications from diabetes, comorbidity, life expectancy, and patient preferences (143). A target hemoglobin A_{1c} level less than 7% based on individualized assessment is a reasonable goal for some but not all patients (143, 144). Younger patients with type 1 diabetes are more likely to benefit from tight glycemic control, whereas elderly patients with several coexisting chronic conditions are least likely to benefit.

Physical Activity

Counseling about physical activity is a critical component of a comprehensive strategy for coronary risk factor modification in patients with stable IHD. Evidence shows that regular exercise reduces coronary heart disease mortality (145). Benefits of exercise have also been shown in patients with stable IHD (45, 146–151). Exercise-based cardiac rehabilitation may ameliorate and reduce reporting of symptoms (146, 150, 152, 153).

Most patients with coronary disease should be encouraged to engage in 30 to 60 minutes of moderate-intensity aerobic activity, such as brisk walking, on most and preferably all days of the week (154). Resistance training can also be beneficial.

Evidence also shows the safety of exercise-based cardiac rehabilitation in patients with documented stable IHD (155–158). Patients at high risk for cardiac complications (that is, those with a history of multiple MIs or cardiac arrest, New York Heart Association functional class 3 or 4 or exercise capacity less than 6 METs [metabolic equivalents], or significant exercise-induced ischemia on treadmill testing) should participate in a medically supervised program for at least 8 to 12 weeks to establish the safety of the prescribed exercise regimen.

Weight Management

Increased body weight has been shown to be associated with coronary events (159). Cardiovascular risk is increased in patients with central obesity, which can be identified by a waist circumference greater than 40 inches in men or greater than 35 inches in women (160, 161). No clinical trials have specifically examined the effects of weight loss on cardiovascular event rates in patients with stable IHD. However, the association of adiposity with other cardiovascular risk factors suggests that weight reduction is beneficial in all overweight and obese patients.

Weight loss can be achieved through reducing caloric intake, nutritional counseling, and behavioral modification therapy. The

ACP recommends (162) that clinicians should 1) counsel all obese patients (defined as those with a BMI ≥ 30 kg/m²) on lifestyle and behavioral modifications, such as appropriate diet and exercise; 2) individually determine the patient's goals for weight loss (these goals may encompass not only weight loss but also changes in other parameters, such as decreasing blood pressure or fasting blood glucose levels); and 3) offer pharmacologic therapy to obese patients who have not achieved their weight loss goals through diet and exercise alone. Regarding pharmacologic agents, however, there needs to be a physician–patient discussion of the drugs' side effects, the lack of long-term safety data, and the temporary nature of the weight loss achieved with medications before initiating therapy. Weight loss is a difficult target, and other adjunct therapies may be appropriate for certain patients.

Smoking Cessation

There is incontrovertible evidence that cigarette smoking is associated with increased risk for cardiovascular disease events (163, 164). In addition, the number of cigarettes smoked is also linked with increased relative risk for cardiovascular disease events (164). Although randomized clinical trials of smoking cessation have not been performed in patients with stable IHD, results of observational studies strongly suggest that smoking cessation is an effective strategy for secondary prevention of coronary events.

The most effective smoking cessation strategies include both nonpharmacologic and medical interventions. Various strategies include physician advice (165); self-help programs, telephone counseling, behavioral therapy, and exercise (166–170); and nicotine replacement therapy (gum, patch, tablet, lozenge, and nasal spray) (171). Physicians should approach smoking cessation using the 5 A's framework (Ask, Advise, Assess, Assist, Arrange), which seeks to understand treatment of tobacco dependence and organize clinicians to provide appropriate treatment (172).

Sustained-release bupropion has demonstrated effectiveness similar to that of nicotine replacement therapy (173). Varenicline, a partial agonist of the $\alpha 4\beta 2$ nicotinic receptor, compares favorably with placebo and with bupropion in clinical trials (174, 175). There have, however, been concerns about possible worsening of pre-existing depression and the risk for suicide due to varenicline. The Food and Drug Administration has issued an alert warning that serious neuropsychiatric symptoms may occur in patients taking this drug (176, 177).

Medical Therapy to Prevent MI and Death in Patients With Stable IHD

Antiplatelet Therapy

Platelet inhibition is indicated in patients with stable IHD to reduce platelet aggregation as a thrombotic response to plaque disruption. A comprehensive meta-analysis showed that aspirin use was associated with a 33% reduction in the risk for serious vascular events, including a 46% decrease in the risk for unstable angina and a 53% decrease in the risk for undergoing coronary angioplasty (178). Aspirin at a dosage of 75 to 162 mg/d is equally as effective as a 325-mg dose in secondary prevention and is associated with a lower risk for bleeding. Doses less than 75 mg

have less proven benefit (178, 179). Aspirin is relatively contraindicated in patients with known allergies to nonsteroidal anti-inflammatory drugs and in patients with the syndrome of asthma, rhinitis, and nasal polyps.

Clopidogrel is a reasonable option if aspirin is contraindicated in patients with stable IHD (180). In certain high-risk patients, a combination of aspirin and clopidogrel has also been shown to be beneficial (181, 182).

Antithrombotic Therapy

The evidence does not support the use of antithrombotic therapy, such as warfarin, in patients with stable IHD in the absence of a specific indication, such as prevention of recurrent venous thromboembolism or chronic atrial fibrillation (183–186). The evidence also does not support dipyridamole (187, 188) or ticlopidine (189, 190) as antiplatelet therapy for patients with stable IHD.

β -Blockers

β -Blockers reduce death and recurrent MI in patients who have sustained an MI and are especially effective when an ST-segment elevation MI is complicated by persistent or recurrent ischemia or tachyarrhythmias early or after the onset of infarction (191, 192). However, no large trials have assessed the effects of β -blockers on survival or coronary event rates in patients with stable IHD.

The results of the APSIS (Angina Prognosis Study in Stockholm), TIBBS (Total Ischemic Burden Bisoprolol Study), and IMAGE (International Multicenter Angina Exercise) studies have shown that β -blockers are more effective than calcium-channel blockers in the control of angina, reduction of cardiovascular events, or need for revascularization (193–195). Although combining β -blocker with calcium-channel blockers increases exercise time and improves cardiovascular outcomes (196, 197), it is important to be aware that a β -blocker given with verapamil or diltiazem may cause bradycardia, atrioventricular block, or excessive fatigue. Also, in patients with stable IHD, combination of a β -blocker with a nitrite is more effective than either monotherapy alone (198, 199). Bisoprolol, carvedilol, and metoprolol have been shown to reduce the risk for death and improve symptoms, clinical status, and quality of life in patients with chronic heart failure with or without CAD (130, 200, 201). The dosing for a β -blocker should be adjusted to limit the heart rate to 55 to 60 beats/min at rest and not to exceed 75% of the exercise heart rate response at the onset of ischemia.

All β -blockers have similar efficacy in patients with stable IHD (202–206). However, there are clinically important differences among β -blockers relating to cardioselectivity, presence of intrinsic sympathomimetic activity, vasodilating properties, and relative lipid solubility in the presence of renal or hepatic impairment. In addition, β -blockers are associated with certain contraindications that should be kept in mind when treating a patient with stable IHD. Absolute contraindications to β -blockers include severe bradycardia, pre-existing high degree of atrioventricular block, sick sinus syndrome, and refractory heart failure. Rel-

ative contraindications include bronchospastic disease or active peripheral arterial disease (β -blockers without vasodilating properties or selective agents at low doses may be used). β -Blockers should be used with caution in patients with type 1 diabetes. Abrupt β -blocker withdrawal should be avoided, and the dose should be tapered during a 1- to 3-week period because of heightened β -receptor density and sensitivity causing a rebound phenomenon associated with an increased risk for acute MI and sudden death.

Renin–Angiotensin–Aldosterone Therapy

ACE Inhibitors. Evidence supports the cardiovascular protective effects of ACE inhibitors and their role in reducing the risks for future ischemic events, such as acute MI and unstable angina (117, 120, 207). Angiotensin-converting enzymes inhibitors are beneficial for all patients with stable IHD and diabetes, LV dysfunction, chronic kidney disease, or cardiovascular history or risk profile similar to those of participants in the HOPE (Heart Outcomes Prevention Evaluation) or EUROPA (EUROPEAN trial On reduction of cardiac events with Perindopril in stable coronary Artery disease) trials (37, 119, 208–211). Although the available ACE inhibitors differ with respect to structure, bioavailability, potency, receptor-binding characteristics, tissue distribution, metabolism, and excretion properties, there is little evidence that these differences are associated with therapeutic advantages. Because the benefits of ACE inhibitors appear to reflect a class effect, the selection of a particular agent should be based on such factors as availability in local formularies, cost, and tolerability.

ARBs. Angiotensin-receptor blockers also play an important role in vascular protection by decreasing blood pressure (212) and reducing LV mass, stroke incidence, and improving outcomes in heart failure (122, 124, 213–216). These drugs should be substituted for ACE inhibitors in patients with stable IHD and hypertension or LV dysfunction who are intolerant of ACE inhibitors (122, 124, 212, 214, 216).

Influenza Vaccination

Influenza is associated with increased mortality and hospitalizations in patients with cardiovascular disease. The World Health Organization, Centers for Disease Control and Prevention, ACP, and AHA/ACC recommend annual vaccination with inactivated vaccine administered intramuscularly against seasonal influenza in all patients with underlying cardiovascular condition (217, 218).

Medical Therapy for Relief of Symptoms in Patients With Stable IHD

β -Blockers

β -Blockers should be used as the initial agents to relieve anginal symptoms in most forms of stable IHD (20, 192, 202, 203). Long-term treatment with β -blockers reduces the ischemic burden and threshold, improves survival, and is generally well-tolerated (191, 192, 202, 203). However, the adverse event profile of β -blockers may limit their use.

Calcium-Channel Blockers

Calcium-channel blockers can be used if β -blockers are contraindicated in a patient or if adverse effects limit their use (219). All 3 classes of calcium-channel blockers improve myocardial oxygen supply and are effective in several angina presentations (220–222). The choice between various calcium-channel blockers depends on individual characteristics of patients, potential drug interactions, and adverse events. Overall, calcium-channel blockers are well-tolerated and adverse effects are generally related to systemic hypotension. Diltiazem is usually the best tolerated of the 3 classes (dihydropyridines, phenylalkylamines, and benzothiazepines). However, use of a β -blocker with verapamil or diltiazem should generally be avoided because of the potential for development of bradycardia, atrioventricular block, or reduced cardiac contractility. Calcium-channel blockers should be used with caution in patients who are taking cyclosporine, carbamazepine, lithium carbonate, amiodarone, or digoxin because of potential drug interactions.

Nitrates

Nitrates are effective in the treatment of all forms of angina and exert their effects through vasodilatation (223), contributing to coronary blood flow redistribution (224), and antithrombotic and antiplatelet effects (225, 226). Long-term nitrate therapy in patients with stable IHD results in improvement in anginal tolerance. All patients should be prescribed sublingual nitroglycerin tablets or nitroglycerin spray for immediate relief of angina. Most patients respond within 5 minutes of taking 1 to 2 sublingual dose or doses of 0.3 to 0.6 mg. If additional doses are necessary, they should be taken at 5-minute intervals, but no more than 1.2 mg within 15 minutes; during this time frame, the patient should seek immediate medical assistance if no relief occurs (227). These products are also effective for prevention of effort-induced angina when administered 5 to 10 minutes before the angina-inducing action, with relief lasting approximately 30 to 40 minutes (228). Long-acting nitrate preparations (such as nitroglycerin, isosorbide dinitrate, and isosorbide-5-mononitrate) are beneficial for treatment of angina when initial therapy with a β -blocker or nondihydropyridine calcium-channel blocker is contraindicated, unacceptable side effects necessitate discontinuation of these therapies, or additional therapy is needed to control angina.

The most common side effects are headache, flushing, and hypotension. All short-acting nitrate preparations may result in hypotension, sometimes severe, and headaches that limit continued patient adherence with these agents. Nitrates are relatively well-tolerated if a titration schedule is used at initiation and with discontinuation.

Ranolazine

Ranolazine inhibits the late inward sodium current, indirectly reducing the sodium-dependent calcium current during ischemic conditions, and leading to improvement in ventricular diastolic tension and oxygen consumption. It is approved for the treatment of chronic angina but represents a fourth-line agent reserved for patients who have contraindications to, do not

respond to, or cannot tolerate β -blockers, calcium-channel blockers, or long-acting nitrates. Ranolazine may be used in combination with β -blockers, nitrates, dihydropyridine, and calcium-channel blockers. The extended-release preparation reduces the frequency of angina, improves exercise performance, and delays the development of exercise-induced angina and ST-segment depression (229–231). Among patients with acute coronary syndromes, ranolazine did not reduce the incidence of MI or death (232). Ranolazine is contraindicated in combination with potent inhibitors of the *CYP3A4* pathway, including ketoconazole (3.2-fold increase in ranolazine plasma levels) and other azole antifungal agents, macrolide antibiotics, HIV protease inhibitors, grapefruit products or juice, and diltiazem. The major adverse effects are constipation, nausea, dizziness, and headache. The incidence of syncope is less than 1%.

Revascularization

Revascularization by coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) is performed to improve survival, symptoms, or both. The decision to perform revascularization should be undertaken in consultation with a multidisciplinary heart team, including an interventional cardiologist and a cardiac surgeon. This team reviews relevant clinical data, determines whether revascularization using PCI or CABG is technically feasible and reasonable, and helps the patient select among available options (233–236).

Studies performed over the past 3 decades have established that in a select subgroup of patients, patients who have undergone CABG have lower mortality than patients treated medically. Because surgical techniques and the effectiveness of medical therapy have both improved over time, however, it is not entirely clear that the earliest studies remain fully applicable. Nonetheless, the strongest evidence that revascularization improves survival has been established for CABG performed in the following subgroups: 1) patients with operable left main coronary artery stenosis greater than 50% (237, 238), 2) patients with significant stenosis in 3 major vessels (with or without involvement of the proximal left anterior descending artery [LAD]) (239–241), 3) patients with significant stenosis in 2 major vessels with involvement of the proximal LAD (239–241), and 4) patients with significant stenosis in a major coronary artery who have survived sudden cardiac death or sustained ventricular tachycardia (242–244).

In general, the anatomical or clinical features that are associated with substantial ischemia and the extent of ischemia on noninvasive testing are predictors for subsequent adverse outcomes. In the most contemporary studies, however, no significant overall improvement in survival has been observed between patients randomly assigned to revascularization and those assigned to GDMT, even among patients who might be regarded as high risk. In the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) study, survival did not improve among patients with diabetes randomly assigned to GDMT plus CABG, although the study was not powered for this end point, excluded patients with significant left main CAD, and included only a small percentage of patients with proximal LAD artery disease or

LV ejection fraction less than 50% (245). In the STICH (Surgical Treatment for Ischemic Heart Failure) trial, in which 1212 patients with an LV ejection fraction of 35% or less and CAD amenable to revascularization were randomly assigned to CABG or medical therapy, there was no significant difference in overall mortality; however, during a median follow-up of 56 months, 28% of patients assigned to CABG died of a cardiovascular cause compared with 33% of those receiving medical therapy (246).

There is less strong evidence that revascularization using CABG (247–250) may enhance survival in patients with involvement of 1 or 2 major arteries, including proximal LAD with severe or extensive (>20% by myocardial perfusion stress imaging) myocardial ischemia (247, 251). In patients with stable IHD who do not meet these criteria, there is only limited evidence, derived from observational studies, that revascularization influences survival. As opposed to patients with acute coronary syndromes, there is no compelling evidence that PCI improves survival for any group of patients with stable IHD. Moreover, PCI may increase the short-term risk for MI (28, 252–254) but does not decrease the long-term risk (28, 245, 252, 253, 255, 256).

Even in patients who are unlikely to experience improvement in survival, revascularization is often performed to relieve anginal symptoms. In general, however, an adequate trial of GDMT should be undertaken before revascularization is contemplated. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial (251) demonstrated that this strategy is effective in the majority of patients with anginal symptoms, including those with considerable ischemia on noninvasive testing. Such patients can be evaluated for revascularization of significant lesions if GDMT is ineffective, poorly tolerated, or contraindicated, and deferring revascularization in this fashion was not associated with any detectable increase in mortality. Coronary stenoses in arteries other than the left main coronary artery that are greater than 70% should be considered significant, and lesions in the 50% to 70% range can be considered potentially significant. These latter lesions require additional evidence of physiologic significance, from either stress testing or intracoronary flow testing (such as fractional flow reserve), to establish their clinical significance (257–259). Clinical correlation between the patient's symptoms, stress test results, and coronary anatomy is essential. In general, the greater the extent and severity of ischemia on noninvasive stress testing, the greater the benefit to be derived from revascularization compared with medical therapy (237, 260–265).

Naturally, patient preferences play an important role in determining the preferred course of therapy, particular in deciding whether to consider revascularization. To effectively participate in decision making, patients must be furnished with accurate information about the relative risks, benefits, and costs of all therapeutic options. When revascularization is the preferred strategy, the choice between CABG and PCI should be based on a variety of factors, including coronary anatomy, coexisting medical conditions, local expertise, likelihood of achieving complete revascularization, and patient preferences. A meta-analysis (266) of studies comparing CABG and PCI found that survival was similar at 1 year after the procedure (96.4% for CABG vs. 96.5%

for PCI) and at 5 years (90.7% vs. 89.7%). The incidence of acute MI was similar at 5 years after CABG (10.9%) and PCI (11.9%). Procedural strokes were more common after CABG (1.2% vs. 0.6%; $P = 0.002$). Relief of angina was more common at 1 year after CABG (84% vs. 75%) and at 5 years (84% vs. 79%; $P < 0.001$ for both). Repeat coronary revascularization was less frequent at 1 year after CABG (3.8% vs. 26.5%; $P < 0.001$) and at 5 years (9.8% vs. 46.1%; $P < 0.001$), although this difference was reduced after introduction of stents.

For details on other recommendations for revascularization, please refer to the ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS guideline for the diagnosis and management of patients with stable IHD (22). See **Figure 2** in the Executive Summary for an algorithm on revascularization to improve survival of patients with stable IHD and **Figure 3** in the Executive Summary for an algorithm on revascularization to improve symptoms of patients with stable IHD.

Special Considerations

Although differences exist in incidence of disease and approaches to diagnosis, the general approach in this guideline would be to apply the recommendations consistently among groups.

Women

Women generally have a lower incidence of IHD than men until older age. In younger women, microvascular disease is more common, and obstructive epicardial CAD is less prevalent. Stable angina is the most frequent initial manifestation of IHD in women, as opposed to acute MI and sudden death in men (267, 268). Atypical chest pain and anginal equivalent symptoms, such as dyspnea, are more common in women, although women still present with similar patterns, duration, and frequency of symptoms. Contrary to earlier perceptions, the prognosis of women with chest pain and nonobstructive disease is not necessarily better (269, 270), and their outcomes after an MI are worse (271–274). The lower prevalence of obstructive disease in conjunction with technical challenges makes the interpretation of ischemia on imaging studies somewhat more difficult. Younger women have higher false-positive rates on stress testing and nuclear imaging studies, which may be due, in part, to attenuation from breast tissue. Data from the COURAGE registry suggest that the benefits of medical therapy alone in comparison with medical therapy plus early PCI were similar for men and women (252, 275). In other studies, the outcomes of revascularization appear to be less favorable among women than men, as the odds of in-hospital mortality after PCI have ranged from 25% to 80% higher for women compared with men (276–280). This trend may have improved in recent years and after accounting for the higher incidence of diabetes and hypertension in women (281). The risk for procedural complications also appears to be significantly higher in women (282). On the basis of these observations, the initial approach to therapy for women with stable IHD should be to prescribe a full regimen of GDMT and to consider revascularization only for patients who do not obtain a satisfactory re-

sponse or who experience unacceptable adverse effects. On the basis of the higher risk associated with PCI in women, it may be reasonable to adopt an even more conservative approach to this procedure than in men.

Older Adults

Coronary artery disease is more likely to be diffuse and more severe in older adults (>75 years). Common coexisting conditions of pulmonary, gastrointestinal, and musculoskeletal systems can cause chest pain, making diagnosis more difficult, even in patients with documented IHD. Physiologic changes in older adults, including alterations in cardiac output through various mechanisms, muscle loss and deconditioning, neuropathies, lung disease, and degenerative joint disease, make stress testing more difficult.

The higher prevalence of stable IHD disease in older adults leads to more false-negative test results. Although the prognostic value of the Duke treadmill score in older adults may be limited (283), exercise stress testing still provides good information for management (284). For patients who are unable to exercise, pharmacologic stress imaging is indicated and yields a similar degree of accuracy compared with testing in younger individuals who present with suspicion for IHD (285–288).

Despite the complexities and concerns related to evaluating and treating elderly patients with stable IHD, findings from the COURAGE and TIME (Trial of Invasive versus Medical therapy in Elderly patients) trials indicated that initial therapy with medical therapy was not significantly less effective than medical therapy plus PCI in relieving angina during a 12-month period. Moreover, considerable evidence indicates that elderly patients have 2- to 7-fold higher odds of mortality after PCI and CABG than do younger patients and that the risk appears to increase monotonically after age 65 years (276, 278–280, 289–291).

It is recommended that management using GDMT be the initial approach in most elderly patients. Given concerns about higher mortality, particularly in patients older than 75 or 80 years, decisions to recommend revascularization should be undertaken only after careful consideration of patient preferences, functional capacity, quality of life, and end-of-life issues (292).

Diabetes Mellitus

Diabetes (types 1 and 2) is an important risk factor for stable IHD. Cardiovascular mortality is 3-fold higher in diabetic men and between 2- and 5-fold higher in diabetic women compared with patients without diabetes (293, 294). Achievement and maintenance of optimal glycemic control and lipid management, along with careful attention to other risk factors (such as hypertension, smoking, and obesity) are paramount. For patients whose symptoms are inadequately managed or who experience intolerable adverse effects, revascularization should be considered. For diabetic patients with extensive coronary disease and active ischemia, early revascularization may be preferable and should be considered. Coronary artery bypass grafting may be associated with lower mortality in diabetic patients with multivessel disease than PCI, but this remains uncertain (295).

Chronic Kidney Disease

Chronic kidney disease is associated with greater risk for developing stable IHD, for its progression, and for worse outcomes (296–299). Physicians should consider creatinine clearance in pharmacotherapy and risk scores for prediction of contrast-induced nephropathy in addition to the use of renal protective strategies to avoid complications related to chronic kidney disease (300).

Obesity

Obese individuals may have limited physical capacity, exaggerated dyspnea on exertion, and excessive breast tissue that impairs imaging, and their weight may exceed the limits of diagnostic equipment (301–303). Enhancements to single-photon emission computed tomography, including prone imaging, and use of intravenous contrast with stress echocardiography may improve accuracy (304–308).

HIV

HIV infection and treatment appear to be associated with an increased risk for premature coronary and cerebrovascular atherosclerosis (309, 310). Acute MI is often the initial manifestation (311). The cause is probably multifactorial and related to both the underlying infection and antiretroviral therapy. The protease inhibitors amprenavir–fosamprenavir with or without ritonavir and lopinavir with ritonavir have the strongest association with risk for acute MI, whereas saquinavir may not be associated (312). Indinavir, lopinavir–ritonavir, didanosine, and abacavir were associated with increased risk for MI (313). Other agents, such as nonnucleoside reverse transcriptase inhibitors, entry inhibitors, and integrase inhibitors, do not appear to be associated with an increase in risk for IHD. Despite the increase in prevalence of IHD among patients with HIV, the absolute increase in incidence of acute MI is relatively low, and overall mortality does not appear to be increased (314, 315). It is likely that this reflects the otherwise enormous benefit conferred by treatment with antiretroviral therapy in the course of HIV infection. Nonetheless, patients receiving antiretroviral therapy should be assessed for cardiovascular risk factors and monitored for signs and symptoms of IHD. It is prudent to recommend a healthy diet, regular physical activity, and avoidance of smoking. Patients with hypercholesterolemia should be managed in a fashion similar to that used for other patients at risk for IHD (316).

Other Considerations

Rheumatoid arthritis has been shown to increase inflammation of coronary artery walls and increase frequency of vulnerable plaques (317). The adjusted rate of stable IHD in systemic lupus erythematosus is at least 50-fold higher than in patients without it.

Socioeconomic Factors

Low socioeconomic status is highly associated with the risk for developing and dying of cardiovascular disease (318, 319). Moreover, members of an ethnic minority (in particular African

Americans and Hispanics) are less likely to receive a wide variety of diagnostic and therapeutic interventions, including preventive medications, cardiac procedures, and access to cardiologists (320, 321). Health care providers and systems should strive to eliminate barriers to care for patients who have stable IHD and are of low socioeconomic status or are ethnic minorities.

Patient Follow-up

The evidence is very limited, especially from high-quality studies, on the efficacy of specific strategies on patient outcomes that can be used to follow up with patients with stable IHD. However, this is an important clinical issue for primary care physicians. Although ACP does not usually issue recommendations unless they are based on high-quality evidence, this guideline summarizes the discussion on this issue that was developed on the basis of expert consensus in the joint ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS guideline (22).

The clinical follow-up of patients with stable IHD seeks to maximize function and to minimize long-term mortality and morbidity. Ongoing reassessment of adherence to and effectiveness of the therapeutic regimen, including clinical response, occurrence of adverse effects, and treatment goals, should be based on evolving scientific evidence and preferences of the patient. Coexisting chronic medical conditions that may directly or indirectly affect the clinical course of stable IHD should be managed effectively.

Unnecessary testing should be avoided. When appropriate, follow-up exercise testing provides reassessment of the anatomical, functional, and prognostic severity of disease. Patients with stable IHD who have accelerating symptoms or decreasing functional capacity require prompt reassessment, and those who develop acute coronary syndromes should be managed according to established guidelines. Patients with stable IHD should be evaluated before elective or emergent surgery according to established perioperative guidelines.

Standard risk assessment tools for coronary disease that were developed from clinical and laboratory evaluation of ambulatory populations suspected of having IHD (as discussed in the guideline on diagnosis of stable IHD) included patients with noncardiac causes of presenting symptoms (67, 322, 323) and probably perform less well in populations of patients with known stable IHD. Moreover, although mortality and morbidity might intuitively be expected to be higher in patients with documented as opposed to suspected IHD, the former group is more likely to be receiving effective therapy to reduce risk, including revascularization; this could account for the generally low and declining risk for death observed in patients with established but stable IHD (119, 252, 324–330). Unfortunately, there is no accepted index for assessing ongoing risk by using clinical variables in patients with stable IHD.

Frequency and Methods

Patients with stable IHD should have a follow-up evaluation every 4 to 12 months. This interval should be 4 to 6 months during the first year of therapy. Annual evaluations are reasonable after the first year of therapy if the patient is stable and reliable

enough to call or make an appointment when angina symptoms become worse or other symptoms occur. In addition, effective communication between the primary care physician and cardiologist is essential when patients are jointly managed.

Key Components of Follow-up

In the follow-up of patients with stable IHD, key components of history include any changes in physical activity or symptoms; response to therapy, adverse effects, and adherence; and development of relevant or new conditions or changes in existing conditions.

Physical Examination

Physical examinations should include weight, blood pressure, and heart rate. Physicians should look for signs of heart failure, such as elevated jugular venous pressure, hepatojugular reflux, pulmonary crackles, new murmurs or gallops, or edema. The vascular examination should identify any change in peripheral pulses or new bruits.

Laboratory Examination

It is reasonable to screen patients not known to have diabetes with a fasting blood glucose measurement every 3 years and to annually measure hemoglobin A_{1c} levels in patients with established diabetes. Lipid profile assessment 6 to 8 weeks after initiation of lipid-lowering drug therapy and then periodically during the first year of therapy is reasonable (46). Routine measurement of hemoglobin, thyroid function, serum electrolytes, renal function, or oxygen saturation is not beneficial and should be done only when required by the patient's history, physical examination, or clinical course.

Electrocardiography

Repeated electrocardiography (ECG) is indicated when 1) medications affecting cardiac conduction are initiated or changed, 2) the anginal pattern changes, 3) symptoms or findings suggestive of a dysrhythmia or conduction abnormality are present, and 4) near or frank syncope occurs. Although periodic recording of standard 12-lead ECG provides a baseline waveform against which tracings taken during symptoms can reasonably be compared, there is no clear evidence showing that routine, periodic ECG is useful in the absence of a change in history or physical examination.

Follow-up Stress Testing

Strategies for the selection and use of noninvasive testing in the evaluation of new or worsening symptoms in patients with documented stable IHD are similar to those in patients with suspected stable IHD. Despite widespread use of follow-up stress testing in patients with stable angina, few published data have established the benefits of this approach. In the absence of a change in clinical status, low-risk patients with an estimated annual mortality rate of less than 1% over each year of the interval do not require repeated stress testing until 3 years after the initial

evaluation. However, stress testing might be useful in high-risk patients with an estimated annual mortality rate greater than 3% because a marked decrease in exercise capacity or a marked increase in ischemic burden can warrant reevaluation of the medical regimen or interventional plan. Examples of such patients are those with a high-risk Duke treadmill score, an ejection fraction less than 50%, and significant CAD in 1 or more major vessels; diabetic patients; and those with multivessel disease who have not undergone CABG. Patients with an intermediate-risk (>1% and <3%) annual mortality rate may merit testing at an interval of 1 to 3 years, but only if decisions regarding a change in pharmacologic management, level of exercise, or revascularization will be directly influenced by the test result or if the patient has persistent symptoms despite adequate GDMT.

Whenever possible, initial and follow-up testing should be performed using the same stress and imaging techniques so that any interval change can more reliably be attributed to alterations in clinical status rather than merely differences in technique. In patients with interpretable results on resting ECG who are capable of exercise, treadmill exercise ECG testing remains the first choice. Loss of the ability to exercise on follow-up testing in and of itself suggests deterioration in functional and clinical status. In general, the diagnostic accuracy of stress testing is similar in patients with and without known stable IHD. A few meta-analyses examining the effect of prior MI on diagnostic accuracy have found that the specificity of exercise ECG was higher in mixed populations (331), whereas the diagnostic performance of exercise echocardiography was reduced. In contrast, the specificity of exercise single-photon emission computed tomography was increased because of the predictive value of total stress perfusion abnormalities, which includes both the risk for ischemia plus infarcted myocardium (332).

As discussed in the ACP guideline on diagnosis of stable IHD, the durability of information gained from a stress test over time varies widely according to the characteristics of the patients and the type of test performed. A normal stress test result is generally associated with a low risk for adverse cardiac events; however, among patients with negative results on perfusion imaging studies, the risk for cardiac death or MI can increase fairly rapidly over a 2-year follow-up period if a number of clinical risk factors are present. Among other groups, the risk remains low over 2 years and can be predicted to remain low for an extended period of time. Factors associated with an earlier increase in risk included diabetes, male sex, older age (≥ 70 years), a history of previous MI or revascularization, and having undergone a pharmacologic stress test rather than an exercise test (333). Among patients who are younger, female, and not diabetic or do not have a history of MI or revascularization, the annual risk for adverse cardiovascular events is predicted to remain less than 1% for as long as 9 years.

Summary

The goals of managing patients with stable IHD include reducing premature cardiovascular death and nonfatal MI while maintaining a level of activity, functional capacity, and quality of life that is satisfactory to the patient. Because of the variation in

symptoms and clinical characteristics among patients, as well as their unique perceptions, expectations, and preferences, there is clearly no single correct approach to any given set of clinical circumstances. Patient education regarding various therapeutic options, appropriate levels of exercise, diet and weight control, and the importance of various clinical manifestations play a key role in achieving the treatment goal. Lifestyle modifications are also critical for all patients with stable IHD to control weight and high blood pressure and manage diabetes.

Various pharmacologic approaches can be used to prevent MI or death in patients with stable IHD, including daily aspirin, β -blockers, ACE inhibitors or ARBs, and influenza vaccination. For patients with symptoms, various pharmacologic options are available to relieve symptoms.

Despite limited evidence for the efficacy of specific strategies for the follow-up of patients with stable IHD, there is an emerging consensus that patients with a variety of chronic illnesses have improved outcomes when they receive coordinated care. Patients with stable IHD require regular monitoring to assess changes in their status, response, and adherence to GDMT.

Recommendations

The recommendations were jointly developed by ACP, ACCF, AHA, AATS, PCNA, and STS; however, ACP translated the ACCF/AHA evidence and recommendation grading system into ACP's guideline grading system (Tables 1 and 2, in the Executive Summary).

Patient Education

Recommendation 1: The organizations recommend that patients with stable IHD should have an individualized education plan to optimize care and promote wellness, including:

A. Education on the importance of medication adherence for managing symptoms and reducing disease progression (Grade: strong recommendation; low-quality evidence).

B. An explanation of medication management and cardiovascular risk reduction strategies in a manner that respects the patient's level of understanding, reading comprehension, and ethnicity (Grade: strong recommendation; moderate-quality evidence).

C. A comprehensive review of all therapeutic options (Grade: strong recommendation; moderate-quality evidence).

D. A description of appropriate levels of exercise with encouragement to maintain recommended levels of daily physical activity (Grade: strong recommendation; low-quality evidence).

E. Introduction to self-monitoring skills (Grade: strong recommendation; low-quality evidence).

F. Information on how to recognize worsening cardiovascular symptoms and take appropriate action (Grade: strong recommendation, low-quality evidence).

Recommendation 2: The organizations recommend that patients with stable IHD should be educated regarding the following lifestyle elements that may influence prognosis (Grade: strong recommendation; low-quality evidence):

A. Weight control and maintenance of a body mass index (BMI) of 18.5 to 24.9 kg/m² and waist circumference less than 40 inches for men and less than 35 inches for women (less for certain racial groups).

B. Lipid management.

C. Blood pressure control.

D. Smoking cessation and avoidance of exposure to second-hand smoke.

E. Individualized medical, nutrition, and lifestyle education for patients with diabetes mellitus to supplement diabetes treatment goals and education.

Risk Factor Modification

Lipid Management. Recommendation 3: The organizations recommend lifestyle modifications for lipid management in all patients with stable IHD, including daily physical activity and weight management (Grade: strong recommendation; moderate-quality evidence).

Recommendation 4: The organizations recommend dietary therapy for all patients, which should include reduced intake of saturated fats (to <7% of total calories), trans-fatty acids (to <1% of total calories), and cholesterol (to <200 mg per day) (Grade: strong recommendation; moderate-quality evidence).

Recommendation 5: The organizations recommend that in addition to therapeutic lifestyle changes, a moderate or high dose of a statin therapy should be prescribed in the absence of contraindications or documented adverse effects. (Grade: strong recommendation; high-quality evidence).

Hypertension. Recommendation 6: The organizations recommend that patients with stable IHD who have high blood pressure should be counseled regarding the need for lifestyle modifications, including maintenance of recommended weight; increased physical activity; moderation of alcohol consumption; limitation of dietary sodium; and emphasis on increased consumption of fresh fruits, vegetables, and low-fat dairy products (Grade: strong recommendation; moderate-quality evidence).

Recommendation 7: The organizations recommend that patients with stable IHD with blood pressure of 140/90 mm Hg or higher should be treated with antihypertensive drug therapy in addition to following a trial of lifestyle modifications (Grade: strong recommendation; high-quality evidence). The specific medications used for treatment of high blood pressure should be based on specific patient characteristics, and may include ACE inhibitors and/or β -blockers, with addition of other drugs, such as thiazide diuretics or calcium-channel blockers, if needed to achieve a goal blood pressure of less than 140/90 mm Hg (Grade: strong recommendation; moderate-quality evidence).

Diabetes. Recommendation 8: The organizations recommend that therapy with rosiglitazone should not be initiated in diabetic patients with stable IHD (Grade: strong recommendation; low-quality evidence).

Physical Activity. Recommendation 9: The organizations recommend risk assessment with a physical activity history to guide prognosis and prescription for all patients. An exercise test should be obtained when clinically indicated (Grade: strong recommendation; moderate-quality evidence). As indicated, based on this assessment, patients with stable IHD should be encouraged to engage in 30 to 60 minutes of moderate-intensity aerobic activity, such as brisk walking, at least 5 days and preferably 7 days of the week, supplemented by an increase in daily activities (such as walking breaks at work, garden-

ing, or household work) to improve cardiorespiratory fitness and motivate patients of the least fit, least active high-risk cohort (bottom 20%) (Grade: strong recommendation; moderate-quality evidence). Medically supervised programs (cardiac rehabilitation) and physician-directed, home-based programs are recommended for at-risk patients at first diagnosis (Grade: strong recommendation; high-quality evidence).

Weight Management. Recommendation 10: The organizations recommend assessing BMI and/or waist circumference at every visit and consistently encouraging weight maintenance/reduction through an appropriate balance of lifestyle physical activity, structured exercise, caloric intake, and formal behavioral programs when indicated to maintain/achieve a BMI between 18.5 and 24.9 kg/m², and waist circumference less than 40 inches in men and less than 35 inches in women (less for certain racial groups) (Grade: strong recommendation; moderate-quality evidence). The initial goal of weight loss therapy should be to reduce body weight by approximately 5% to 10% from baseline. With success, further weight loss can be attempted if indicated (Grade: strong recommendation; low-quality evidence).

Smoking Cessation. Recommendation 11: The organizations recommend that smoking cessation and avoidance of exposure to environmental tobacco smoke at work and at home should be encouraged for all patients with stable IHD. A stepwise strategy for smoking cessation (Ask, Advise, Assess, Assist, Arrange), follow-up, referral to special programs, and pharmacotherapy are recommended (Grade: strong recommendation; moderate-quality evidence).

Risk Factor Reduction Strategies of Unproven Benefits. Recommendation 12: The organizations recommend that estrogen therapy should not be initiated in postmenopausal women with stable IHD with the intent of reducing cardiovascular risk or improving clinical outcomes (Grade: strong recommendation; high-quality evidence).

Recommendation 13: The organizations recommend that vitamin C, vitamin E, and β -carotene supplementation should not be used with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with stable IHD (Grade: strong recommendation; high-quality evidence).

Recommendation 14: The organizations recommend that treatment of elevated homocysteine with folate and/or vitamins B₆ and B₁₂ should not be used with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with stable IHD (Grade: strong recommendation; high-quality evidence).

Recommendation 15: The organizations recommend that chelation therapy should not be used with the intent of improving symptoms or reducing cardiovascular risk in patients with stable IHD (Grade: strong recommendation; low-quality evidence).

Recommendation 16: The organizations recommend that treatment with garlic, coenzyme Q₁₀, selenium, or chromium should not be used with the intent of reducing cardiovascular risk or improving clinical outcomes in patients with stable IHD (Grade: strong recommendation; low-quality evidence).

Medical Therapy to Prevent MI and Death in Patients With Stable IHD

Recommendation 17: The organizations recommend that aspirin, 75 to 162 mg daily, should be continued indefinitely in the

absence of contraindications in patients with stable IHD (Grade: strong recommendation; high-quality evidence).

Recommendation 18: The organizations recommend treatment with clopidogrel as a reasonable option when aspirin is contraindicated in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Recommendation 19: The organizations recommend that dipyridamole should not be used as antiplatelet therapy for patients with stable IHD (Grade: strong recommendation; low-quality evidence).

Recommendation 20: The organizations recommend that β -blocker therapy should be initiated and continued for 3 years in all patients with normal LV function following MI or acute coronary syndromes (Grade: strong recommendation; moderate-quality evidence).

Recommendation 21: The organizations recommend that metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction \leq 40%) with heart failure or prior MI, unless contraindicated (Grade: strong recommendation; high-quality evidence).

Recommendation 22: The organizations recommend that ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction \leq 40%), or chronic kidney disease, unless contraindicated (Grade: strong recommendation; high-quality evidence).

Recommendation 23: The organizations recommend ARBs for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors (Grade: strong recommendation; high-quality evidence).

Recommendation 24: The organizations recommend an annual influenza vaccine for patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Medical Therapy for Relief of Symptoms in Patients With Stable IHD

Recommendation 25: The organizations recommend that β -blockers should be prescribed as initial therapy for relief of symptoms in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Recommendation 26: The organizations recommend that calcium-channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β -blockers are contraindicated or cause unacceptable side effects in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Recommendation 27: The organizations recommend that calcium-channel blockers or long-acting nitrates, in combination with β -blockers, should be prescribed for relief of symptoms when initial treatment with β -blockers is unsuccessful in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Recommendation 28: The organizations recommend that sublingual nitroglycerin or nitroglycerin spray should be used for immediate relief of angina in patients with stable IHD (Grade: strong recommendation; moderate-quality evidence).

Alternative Therapy for Relief of Symptoms in Patients With Stable IHD

Recommendation 29: The organizations recommend that acupuncture should not be used for the purpose of improving symptoms or reducing cardiovascular risk in stable IHD patients (Grade: strong recommendation; low-quality evidence).

Revascularization

Recommendation 30: The organizations recommend that a shared decision-making approach should be utilized when making decisions about revascularization in patients with unprotected left main or complex coronary artery disease and should include a cardiac surgeon, an interventional cardiologist, and the patient (Grade: strong recommendation; low-quality evidence).

Revascularization to Improve Survival. *Recommendation 31: The organizations recommend CABG to improve survival for patients with significant ($\geq 50\%$ diameter stenosis) left main coronary artery stenosis (Grade: strong recommendation; moderate-quality evidence).*

Recommendation 32: The organizations recommend that PCI to improve survival should not be performed in stable patients with significant ($\geq 50\%$ diameter stenosis) unprotected left main CAD who have unfavorable anatomy for PCI and who are good candidates for CABG (Grade: strong recommendation; moderate-quality evidence).

Recommendation 33: The organizations recommend the use of CABG to improve survival in patients with significant ($\geq 70\%$ diameter) stenoses in 3 major coronary arteries (with or without involvement of the proximal left anterior descending artery) or in the proximal left anterior descending artery plus 1 other major coronary artery (Grade: strong recommendation; moderate-quality evidence).

Recommendation 34: The organizations recommend the use of CABG or PCI to improve survival in survivors of sudden cardiac death with presumed ischemia-mediated ventricular tachycardia caused by significant ($\geq 70\%$ diameter) stenosis in a major coronary artery (Grade: strong recommendation; moderate-quality evidence for CABG, low-quality evidence for PCI).

Recommendation 35: The organizations recommend that CABG or PCI should not be performed with the primary or sole intent to improve survival in patients with stable IHD with 1 or more coronary stenoses that are not anatomically or functionally significant (for example, $< 70\%$ diameter non-left main coronary artery stenosis, fractional flow reserve > 0.80 , no or only mild ischemia on noninvasive testing), involve only the left circumflex or right coronary artery, or subtend only a small area of viable myocardium (Grade: strong recommendation; moderate-quality evidence).

Revascularization to Improve Symptoms. *Recommendation 36: The organizations recommend the use of CABG or PCI to improve symptoms in patients with 1 or more significant ($\geq 70\%$ diameter) coronary artery stenoses amenable to revascularization and unacceptable angina despite GDMT (Grade: strong recommendation; high-quality evidence).*

Recommendation 37: The organizations recommend that CABG or PCI to improve symptoms should not be performed in patients who do not meet anatomical ($\geq 50\%$ diameter left main or

$\geq 70\%$ non-left main stenosis diameter) or physiologic (for example, abnormal fractional flow reserve) criteria for revascularization (Grade: strong recommendation; low-quality evidence).

Recommendation 38: The organizations recommend that PCI with coronary stenting (bare-metal stent or drug-eluting stent) should not be performed if the patient is not likely to be able to tolerate and comply with dual antiplatelet therapy for the appropriate duration of treatment based on the type of stent implanted (Grade: strong recommendation; moderate-quality evidence).

Patient Follow-up

Recommendation 39: The organizations recommend that patients with stable IHD should receive periodic follow-up at least annually that includes all of the following (Grade: strong recommendation; low-quality evidence):

A. Assessment of symptoms and clinical function.

B. Surveillance for complications of stable IHD, including heart failure and arrhythmias.

C. Monitoring of cardiac risk factors.

D. Assessment of the adequacy of and adherence to recommended lifestyle changes and medical therapy.

Recommendation 40: The organizations recommend assessment of LV ejection fraction and segmental wall motion by echocardiography or radionuclide imaging in patients with new or worsening heart failure or evidence of intervening MI by history or ECG (Grade: strong recommendation; low-quality evidence).

Recommendation 41: The organizations recommend that measurement of LV function with a technology such as echocardiography or radionuclide imaging should not be used for routine periodic reassessment of patients who have not had a change in clinical status or who are at low risk of adverse cardiovascular events (Grade: strong recommendation; low-quality evidence).

Recommendation 42: The organizations recommend standard exercise ECG in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina and who have 1) at least moderate physical functioning and no disabling comorbidity and 2) an interpretable ECG (Grade: strong recommendation; moderate-quality evidence).

Recommendation 43: The organizations recommend exercise with radionuclide myocardial perfusion imaging or echocardiography in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina, and who have a) at least moderate physical functioning or no disabling comorbidity but b) an uninterpretable ECG (Grade: strong recommendation; moderate-quality evidence).

Recommendation 44: The organizations recommend that pharmacologic stress imaging with radionuclide myocardial perfusion imaging, echocardiography, or cardiac magnetic resonance imaging should not be used in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina and who are capable of at least moderate physical functioning or have no disabling comorbidity (Grade: strong recommendation; low-quality evidence).

Recommendation 45: The organizations recommend pharmacologic stress imaging using radionuclide myocardial perfusion or echocardiography in patients with known stable IHD who have new

or worsening symptoms not consistent with unstable angina and who are incapable of at least moderate physical functioning or have disabling comorbidity (Grade: strong recommendation; moderate-quality evidence).

Recommendation 46: The organizations recommend that standard exercise ECG testing should not be performed in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina and who a) are incapable of at least moderate physical functioning or have disabling comorbidity or b) have an uninterpretable ECG (Grade: strong recommendation; low-quality evidence).

Recommendation 47: The organizations recommend that coronary/cardiac computed tomography angiography should not be performed for assessment of native coronary arteries with known moderate or severe calcification or of coronary stents less than 3 mm in diameter in patients with known stable IHD who have new or worsening symptoms not consistent with unstable angina, irrespective of ability to exercise (Grade: strong recommendation; moderate-quality evidence).

Recommendation 48: The organizations recommend that radionuclide myocardial perfusion imaging, echocardiography, or cardiac magnetic resonance imaging, with either exercise or pharmacologic stress or coronary/cardiac computed tomography angiography, should not be used for follow-up assessment in patients with stable IHD, if performed more frequently than at a) 5-year intervals after CABG or b) 2-year intervals after PCI (Grade: strong recommendation; low-quality evidence).

APPENDIX REFERENCES

19. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. *Health Aff.* 2007;26:38-48.
20. Centers for Medicare & Medicaid Services. Medicare & Medicaid Statistical Supplement. 2008. Accessed at www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareMedicaidStatSupp/2008.html on 30 August 2012.
21. Qaseem A, Fihn SD, Williams S, Dallas P, Owens DK, Shekelle P; for the Clinical Guidelines Committee of the American College of Physicians. Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med.* 2012;157:729-34.
22. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas P, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2012. [Forthcoming].
23. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al; AHA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol.* 2006;47:2130-9. [PMID: 16697342]
24. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med.* 2006;354:1706-17. [PMID: 16531616]
25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994;344:1383-9. [PMID: 7968073]
26. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med.* 1996;335:1001-9. [PMID: 8801446]
27. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med.* 1998;339:1349-57. [PMID: 9841303]
28. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med.* 1999;341:70-6. [PMID: 10395630]
29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet.* 2002;360:7-22. [PMID: 12114036]
30. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med.* 2005;352:20-8. [PMID: 15635109]
31. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med.* 2005;352:1425-35. [PMID: 15755765]
32. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al. Effectiveness of statin therapy in adults with coronary heart disease. *Arch Intern Med.* 2004;164:1427-36. [PMID: 15249352]
33. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med.* 1998;339:489-97. [PMID: 9709041]
34. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. *Arch Intern Med.* 1993;153:578-81. [PMID: 8439221]
35. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. *Nat Med.* 2002;8:1257-62. [PMID: 12411953]
36. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med.* 2000;342:145-53. [PMID: 10639539]
37. Fox KM; EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet.* 2003;362:782-8. [PMID: 13678872]
38. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation.* 2008;117:e25-146. [PMID: 18086926]
39. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet.* 2004;364:937-52. [PMID: 15364185]
40. Joint Commission. The Joint Commission announces the 2008 National Patient Safety Goals and Requirements. *Jt Comm Perspect.* 2007;27:1, 9-22. [PMID: 17682787]
41. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al; Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation.* 2007;115:1481-501. [PMID: 17309915]
42. Patient education. American Academy of Family Physicians. *Am Fam Physician.* 2000;62:1712-4. [PMID: 11037081]
43. Miller N, Taylor C. Lifestyle Management for Persons with Coronary Heart Disease. Current Issues in Cardiac Rehabilitation. Monograph No. 2. Champaign, IL: Human Kinetics; 1995.
44. DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. *Ann Intern Med.* 1994;120:721-9. [PMID: 8147544]
45. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis

and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). *Circulation*. 1994;89:975-90. [PMID: 8124838]

46. **National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)**. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143-421. [PMID: 12485966]

47. **Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al; Writing Group of the PREMIER Collaborative Research Group**. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA*. 2003;289:2083-93. [PMID: 12709466]

48. **Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators**. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. 2005;366:1267-78. [PMID: 16214597]

49. **Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute**. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003;42:1206-52. [PMID: 14656957]

50. **Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al; American Heart Association Nutrition Committee**. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation*. 2006;114:82-96. [PMID: 16785338]

51. **Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al; American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and Prevention**. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation*. 2003;107:3109-16. [PMID: 12821592]

52. **Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, et al; American Heart Association Council on Nutrition, Physical Activity, and Metabolism**. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. *Circulation*. 2007;115:2358-68. [PMID: 17468391]

53. **National Heart, Lung, and Blood Institute**. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda, MD: National Institutes of Health; 2008.

54. **Oka R, Kobayashi J, Yagi K, Tanii H, Miyamoto S, Asano A, et al**. Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. *Diabetes Res Clin Pract*. 2008;79:474-81. [PMID: 18031862]

55. **Tan CE, Ma S, Wai D, Chew SK, Tai ES**. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? *Diabetes Care*. 2004;27:1182-6. [PMID: 15111542]

56. **Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al; American Heart Association**. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*. 2007;115:114-26. [PMID: 17192512]

57. **Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al; American College of Cardiology. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society**. *Circulation*. 2005;112:e154-235. [PMID: 16160202]

58. **Bosworth HB, Olsen MK, Dudley T, Orr M, Neary A, Harrelson M, et al**. The Take Control of Your Blood pressure (TCYB) study: study design and methodology. *Contemp Clin Trials*. 2007;28:33-47. [PMID: 16996808]

59. **The 2004 United States Surgeon General's Report: The Health Consequences of Smoking**. *N S W Public Health Bull*. 2004;15:107. [PMID: 15543245]

60. **Critchley JA, Capewell S**. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA*. 2003;290:86-97. [PMID: 12837716]

61. **McGillion M, Watt-Watson J, LeFort S, Stevens B**. Positive shifts in the perceived meaning of cardiac pain following a psychoeducation program for chronic stable angina. *Can J Nurs Res*. 2007;39:48-65. [PMID: 17679585]

62. **Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM**. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. *Int J Clin Pract*. 2008;62:338-51. [PMID: 18199282]

63. **Rao SV, Schulman KA, Curtis LH, Gersh BJ, Jollis JG**. Socioeconomic status and outcome following acute myocardial infarction in elderly patients. *Arch Intern Med*. 2004;164:1128-33. [PMID: 15159271]

64. **The Lipid Research Clinics Coronary Primary Prevention Trial results. I**. Reduction in incidence of coronary heart disease. *JAMA*. 1984;251:351-64. [PMID: 6361299]

65. **The Lipid Research Clinics Coronary Primary Prevention Trial results. II**. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA*. 1984;251:365-74. [PMID: 6361300]

66. **Stamler J, Wentworth D, Neaton JD**. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA*. 1986;256:2823-8. [PMID: 3773199]

67. **Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB**. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97:1837-47. [PMID: 9603539]

68. **Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al**. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. *N Engl J Med*. 1990;322:1700-7. [PMID: 2342536]

69. **Rossouw JE, Lewis B, Rifkind BM**. The value of lowering cholesterol after myocardial infarction. *N Engl J Med*. 1990;323:1112-9. [PMID: 2215579]

70. **Wong ND, Wilson PW, Kannel WB**. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. *Ann Intern Med*. 1991;115:687-93. [PMID: 1929036]

71. **Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, et al**. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. *Arterioscler Thromb Vasc Biol*. 1998;18:441-9. [PMID: 9514413]

72. **Schaefer EJ, Lamon-Fava S, Ausman LM, Ordovas JM, Clevidence BA, Judd JT, et al**. Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets. *Am J Clin Nutr*. 1997;65:823-30. [PMID: 9062535]

73. **Schaefer EJ, Lichtenstein AH, Lamon-Fava S, Contois JH, Li Z, Rasmussen H, et al**. Efficacy of a National Cholesterol Education Program Step 2 diet in normolipidemic and hypercholesterolemic middle-aged and elderly men and women. *Arterioscler Thromb Vasc Biol*. 1995;15:1079-85. [PMID: 7627699]

74. **Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM**. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr*. 1999;69:632-46. [PMID: 10197564]

75. **Durstine JL, Grandjean PW, Cox CA, Thompson PD**. Lipids, lipoproteins, and exercise. *J Cardiopulm Rehabil*. 2002;22:385-98. [PMID: 12464825]

76. **Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL, DuBose KD**. Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. *Sports Med*. 2001;31:1033-62. [PMID: 11735685]

77. **Leon AS, Sanchez OA**. Response of blood lipids to exercise training alone or combined with dietary intervention. *Med Sci Sports Exerc*. 2001;33:S502-15; discussion S528-9. [PMID: 11427777]

78. **Heart Protection Study Collaborative Group**. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:23-33. [PMID: 12114037]

79. **Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al; Incremental Decrease in End Points Through Aggressive Lipid**

- Lowering (IDEAL) Study Group.** High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA*. 2005;294:2437-45. [PMID: 16287954]
80. **ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.** Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA*. 2002;288:2998-3007. [PMID: 12479764]
81. **Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.** Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*. 2004;350:1495-504. [PMID: 15007110]
82. **Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al; ASCOT investigators.** Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*. 2003;361:1149-58. [PMID: 12686036]
83. **Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al; PROSPER study group.** PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002;360:1623-30. [PMID: 12457784]
84. **Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Study Group.** Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195-207. [PMID: 18997196]
85. **Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al; National Heart, Lung, and Blood Institute.** Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110:227-39. [PMID: 15249516]
86. **Whelton SP, He J, Whelton PK, Muntner P.** Meta-analysis of observational studies on fish intake and coronary heart disease. *Am J Cardiol*. 2004;93:1119-23. [PMID: 15110203]
87. **Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.** *Lancet*. 1999;354:447-55. [PMID: 10465168]
88. **Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, et al.** An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. *Heart*. 2001;85:544-8. [PMID: 11303007]
89. **Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al.** Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. *Arch Intern Med*. 2001;161:1413-9. [PMID: 11386890]
90. **Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration.** Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903-13. [PMID: 12493255]
91. **Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.** *BMJ*. 1992;304:405-12. [PMID: 1445513]
92. **Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.** *JAMA*. 1991;265:3255-64. [PMID: 2046107]
93. **MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.** *Br Med J (Clin Res Ed)*. 1985;291:97-104. [PMID: 2861880]
94. **The effect of treatment on mortality in "mild" hypertension: results of the hypertension detection and follow-up program.** *N Engl J Med*. 1982;307:976-80. [PMID: 7110301]
95. **Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.** *JAMA*. 1979;242:2562-71. [PMID: 490882]
96. **Collins R, Peto R.** Antihypertensive Drug Therapy: Effects on Stroke and Coronary Heart Disease. Oxford, UK: Blackwell Scientific Publications; 1994.
97. **Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-Year findings of the hypertension detection and follow-up program.** *Hypertension*. 1984;6:198-206. [PMID: 6724670]
98. **Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al.** Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. *JAMA*. 1998;279:839-46. [PMID: 9515998]
99. **Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group.** *Arch Intern Med*. 1997;157:657-67. [PMID: 9080920]
100. **Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, et al.** Weight loss intervention in phase I of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. *Arch Intern Med*. 1993;153:849-58. [PMID: 8466377]
101. **Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM.** Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2003;42:878-84. [PMID: 12975389]
102. **Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, et al; Trials for the Hypertension Prevention Research Group.** Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. *Ann Intern Med*. 2001;134:1-11. [PMID: 11187414]
103. **Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al.** A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med*. 1997;336:1117-24. [PMID: 9099655]
104. **Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al; DASH-Sodium Collaborative Research Group.** Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med*. 2001;344:3-10. [PMID: 11136953]
105. **MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP.** Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. *Lancet*. 1989;2:1244-7. [PMID: 2573761]
106. **He FJ, MacGregor GA.** Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. *J Hum Hypertens*. 2002;16:761-70. [PMID: 12444537]
107. **Whelton SP, Chin A, Xin X, He J.** Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. *Ann Intern Med*. 2002;136:493-503. [PMID: 11926784]
108. **Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK.** Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2001;38:1112-7. [PMID: 11711507]
109. **Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al; HYVET Study Group.** Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008;358:1887-98. [PMID: 18378519]
110. **Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al.** Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet*. 1997;350:757-64. [PMID: 9297994]
111. **Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR.** The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? *JAMA*. 1991;265:489-95. [PMID: 1824642]
112. **MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al.** Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet*. 1990;335:765-74. [PMID: 1969518]
113. **Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al.** Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? *Ann Intern Med*. 2006;144:884-93. [PMID: 16785477]
114. **ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.** Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288:2981-97. [PMID: 12479763]

115. **Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration.** Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362:1527-35. [PMID: 14615107]
116. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). *Lancet*. 1997;349:1857-63. [PMID: 9217756]
117. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. *Lancet*. 1993;342:821-8. [PMID: 8104270]
118. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med*. 1991;325:293-302. [PMID: 2057034]
119. **Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al; PEACE Trial Investigators.** Angiotensin-converting-enzyme inhibition in stable coronary artery disease. *N Engl J Med*. 2004;351:2058-68. [PMID: 15531767]
120. **Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, et al.** A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med*. 1995;333:1670-6. [PMID: 7477219]
121. **Wright JT Jr, Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, et al; African American Study of Kidney Disease and Hypertension Study Group.** Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. *Arch Intern Med*. 2002;162:1636-43. [PMID: 12123409]
122. **Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; RENAAL Study Investigators.** Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*. 2001;345:861-9. [PMID: 11565518]
123. **Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators.** A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med*. 2001;345:1667-75. [PMID: 11759645]
124. **Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al; Collaborative Study Group.** Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*. 2001;345:851-60. [PMID: 11565517]
125. **Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al; ONTARGET Investigators.** Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008;358:1547-59. [PMID: 18378520]
126. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. *Circulation*. 1994;90:1765-73. [PMID: 7923660]
127. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. *JAMA*. 1982;247:1707-14. [PMID: 7038157]
128. **Dargie HJ.** Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet*. 2001;357:1385-90. [PMID: 11356434]
129. **Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacs P, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group.** Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*. 2001;344:1651-8. [PMID: 11386263]
130. **Tepper D.** Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Congest Heart Fail*. 1999;5:184-185. [PMID: 12189311]
131. **Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, et al.** Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. *Am J Cardiol*. 1987;59:750-5. [PMID: 3825934]
132. **Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al.** Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. *Diabetologia*. 2003;46:760-5. [PMID: 12774166]
133. **Gu K, Cowie CC, Harris MI.** Diabetes and decline in heart disease mortality in US adults. *JAMA*. 1999;281:1291-7. [PMID: 10208144]
134. **Kannel WB, McGee DL.** Diabetes and cardiovascular disease. The Framingham study. *JAMA*. 1979;241:2035-8. [PMID: 430798]
135. **Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, et al.** A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. *Arch Intern Med*. 1991;151:1141-7. [PMID: 2043016]
136. **Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, et al.** Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. *J Am Coll Cardiol*. 1993;22:1141-54. [PMID: 8409054]
137. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med*. 1993;329:977-86. [PMID: 8366922]
138. **Reichard P, Nilsson BY, Rosenqvist U.** The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. *N Engl J Med*. 1993;329:304-9. [PMID: 8147960]
139. **Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.** Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*. 2005;353:2643-53. [PMID: 16371630]
140. **Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al; ADVANCE Collaborative Group.** Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358:2560-72. [PMID: 18539916]
141. **Dluhy RG, McMahan GT.** Intensive glycemic control in the ACCORD and ADVANCE trials [Editorial]. *N Engl J Med*. 2008;358:2630-3. [PMID: 18539918]
142. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352:837-53. [PMID: 9742976]
143. **Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians.** Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. *Ann Intern Med*. 2007;147:417-22. [PMID: 17876024]
144. **American Diabetes Association.** Standards of medical care in diabetes—2008. *Diabetes Care*. 2008;31 Suppl 1:S12-54. [PMID: 18165335]
145. **Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al; African-American Heart Failure Trial Investigators.** Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med*. 2004;351:2049-57. [PMID: 15533851]
146. **Froelicher V, Jensen D, Genter F, Sullivan M, McKirnan MD, Witzum K, et al.** A randomized trial of exercise training in patients with coronary heart disease. *JAMA*. 1984;252:1291-7. [PMID: 6381770]
147. **Hambrecht R, Niebauer J, Marburger C, Grunze M, Kälberer B, Hauer K, et al.** Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. *J Am Coll Cardiol*. 1993;22:468-77. [PMID: 8335816]
148. **May GA, Nagle FJ.** Changes in rate-pressure product with physical training of individuals with coronary artery disease. *Phys Ther*. 1984;64:1361-6. [PMID: 6473517]
149. **Oldridge NB, McCartney N, Hicks A, Jones NL.** Improvement in maximal isokinetic cycle ergometry with cardiac rehabilitation. *Med Sci Sports Exerc*. 1989;21:308-12. [PMID: 2733581]
150. **Ornish D, Scherwitz LW, Doody RS, Kesten D, McLanahan SM, Brown SE, et al.** Effects of stress management training and dietary changes in treating ischemic heart disease. *JAMA*. 1983;249:54-9. [PMID: 6336794]
151. **Sebrechts CP, Klein JL, Ahnve S, Froelicher VF, Ashburn WL.** Myocardial perfusion changes following 1 year of exercise training assessed by thallium-201 circumferential count profiles. *Am Heart J*. 1986;112:1217-26. [PMID: 3491531]
152. **Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, et al.** Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. *Circulation*. 1992;86:1-11. [PMID: 1617762]
153. **Todd IC, Ballantyne D.** Effect of exercise training on the total ischaemic burden: an assessment by 24 hour ambulatory electrocardiographic monitoring. *Br Heart J*. 1992;68:560-6. [PMID: 1467049]

154. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al; American College of Sports Medicine. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Circulation*. 2007;116:1081-93. [PMID: 17671237]
155. Digenio AG, Sim JG, Dowdeswell RJ, Morris R. Exercise-related cardiac arrest in cardiac rehabilitation. The Johannesburg experience. *S Afr Med J*. 1991;79:188-91. [PMID: 1996434]
156. Franklin BA, Bonzheim K, Gordon S, Timmis GC. Safety of medically supervised outpatient cardiac rehabilitation exercise therapy: a 16-year follow-up. *Chest*. 1998;114:902-6. [PMID: 9743182]
157. Van Camp SP, Peterson RA. Cardiovascular complications of outpatient cardiac rehabilitation programs. *JAMA*. 1986;256:1160-3. [PMID: 3735650]
158. Vongvanich P, Paul-Labrador MJ, Merz CN. Safety of medically supervised exercise in a cardiac rehabilitation center. *Am J Cardiol*. 1996;77:1383-5. [PMID: 8677889]
159. Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al; for the BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. *Arch Intern Med*. 2007;167:1720-8. [PMID: 17846390]
160. Hsieh SD, Yoshinaga H. Abdominal fat distribution and coronary heart disease risk factors in men-waist/height ratio as a simple and useful predictor. *Int J Obes Relat Metab Disord*. 1995;19:585-9. [PMID: 7489031]
161. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. *Am J Epidemiol*. 1995;141:1117-27. [PMID: 7771450]
162. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2005;142:525-31. [PMID: 15809464]
163. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. *Br Med J*. 1976;2:1525-36. [PMID: 1009386]
164. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. *N Engl J Med*. 1987;317:1303-9. [PMID: 3683458]
165. Gorin SS, Heck JE. Meta-analysis of the efficacy of tobacco counseling by health care providers. *Cancer Epidemiol Biomarkers Prev*. 2004;13:2012-22. [PMID: 15598756]
166. Hughes JR. Motivating and helping smokers to stop smoking. *J Gen Intern Med*. 2003;18:1053-7. [PMID: 14687265]
167. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. *Cochrane Database Syst Rev*. 2005:CD001292. [PMID: 15846616]
168. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. *Cochrane Database Syst Rev*. 2005:CD001007. [PMID: 15846610]
169. Stead LF, Lancaster T, Perera R. Telephone counselling for smoking cessation. *Cochrane Database Syst Rev*. 2003:CD002850. [PMID: 12535442]
170. Ussher M. Exercise interventions for smoking cessation. *Cochrane Database Syst Rev*. 2005:CD002295. [PMID: 15674895]
171. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev*. 2004:CD000146. [PMID: 15266423]
172. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. *Cochrane Database Syst Rev*. 2003:CD003041. [PMID: 14583958]
173. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev*. 2004:CD000031. [PMID: 15494986]
174. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296:47-55. [PMID: 16820546]
175. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296:56-63. [PMID: 16820547]
176. Food and Drug Administration. Information for Healthcare Professionals. Varenicline (marketed as Chantix). 1 February 2008. Accessed at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124818.htm on 31 August 2012.
177. Food and Drug Administration. Public Health Advisory. Important Information on Chantix (varenicline). 2008. Accessed at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/PublicHealthAdvisories/ucm051136.htm on 31 August 2012.
178. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86. [PMID: 11786451]
179. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. *Circulation*. 2003;108:1682-7. [PMID: 14504182]
180. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet*. 1996;348:1329-39. [PMID: 8918275]
181. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*. 2001;345:494-502. [PMID: 11519503]
182. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA*. 2002;288:2411-20. [PMID: 12435254]
183. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. *J Am Coll Cardiol*. 2003;41:625-69S. [PMID: 12644343]
184. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. *Circulation*. 2001;104:3063-8. [PMID: 11748101]
185. Martini CH, Doggen CJ, Cavallini C, Rosendaal FR, Mannucci PM. No effect of polymorphisms in prothrombotic genes on the risk of myocardial infarction in young adults without cardiovascular risk factors [Letter]. *J Thromb Haemost*. 2005;3:177-9. [PMID: 15634285]
186. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. *Circulation*. 2003;107:1117-22. [PMID: 12615788]
187. Balsano F, Rizzon P, Violi F, Scutrinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. *Circulation*. 1990;82:17-26. [PMID: 2194694]
188. Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. *Chest*. 1995;108:247S-257S. [PMID: 7555180]
189. Jagathesan R, Rosen SD, Foale RA, Camici PG, Picano E. Effects of long-term oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: A substudy of the persantine in stable angina (PISA) study. *J Cardiovasc Pharmacol*. 2006;48:110-6. [PMID: 17031264]
190. Tsuya T, Okada M, Horie H, Ishikawa K. Effect of dipyridamole at the usual oral dose on exercise-induced myocardial ischemia in stable angina pectoris. *Am J Cardiol*. 1990;66:275-8. [PMID: 2195863]
191. Chae C, Hennekens C. Beta-Blockers. Philadelphia: WB Sanders; 1999.
192. Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O'Neill WW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? *J Am Coll Cardiol*. 2004;43:1773-9. [PMID: 15145098]
193. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). *Circulation*. 1994;90:762-8. [PMID: 8044945]

194. Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Angina Prognosis Study in Stockholm. *Cardiologia*. 1995;40:301. [PMID: 8903053]
195. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. *J Am Coll Cardiol*. 1995;25:231-8. [PMID: 7798508]
196. Savonitto S, Ardissio D, Egstrup K, Rasmussen K, Bae EA, Omland T, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. *J Am Coll Cardiol*. 1996;27:311-6. [PMID: 8557899]
197. Emanuelsson H, Egstrup K, Nikus K, Ellström J, Glud T, Pater C, et al. Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group. *Am Heart J*. 1999;137:854-62. [PMID: 10220634]
198. Waysbort J, Meshulam N, Brunner D. Isosorbide-5-mononitrate and atenolol in the treatment of stable exertional angina. *Cardiology*. 1991;79 Suppl 2:19-26. [PMID: 1760824]
199. Krepp HP. Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris. *Cardiology*. 1991;79 Suppl 2:14-8. [PMID: 1760823]
200. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med*. 1996;334:1349-55. [PMID: 8614419]
201. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies—CIBIS and CIBIS II. *Cardiac Insufficiency Bisoprolol Study*. *Am Heart J*. 2002;143:301-7. [PMID: 11835035]
202. Frishman WH, Heiman M, Soberman J, Greenberg S, Eff J. Comparison of celiprolol and propranolol in stable angina pectoris. *Celiprolol International Angina Study Group*. *Am J Cardiol*. 1991;67:665-70. [PMID: 1672481]
203. Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. *Betaxolol Investigators Group*. *Am J Cardiol*. 1990;65:577-82. [PMID: 2178381]
204. Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. *Vasc Health Risk Manag*. 2007;3:235-42. [PMID: 17580734]
205. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O'Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. *Eur J Clin Pharmacol*. 1997;52:95-100. [PMID: 9174677]
206. Rafferty EB. The preventative effects of vasodilating beta-blockers in cardiovascular disease. *Eur Heart J*. 1996;17 Suppl B:30-8. [PMID: 8733069]
207. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med*. 1992;327:669-77. [PMID: 1386652]
208. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000;342:154-60. [PMID: 10639540]
209. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, et al; QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. *Am J Cardiol*. 2001;87:1058-63. [PMID: 11348602]
210. Pepine CJ, Probstfield J. A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients. 2004. Accessed at http://vbwg.org/Resources/Monograph/33/CME_monograph.pdf on ** August 2012.
211. Verma S, Mamdani MM, Al-Omran M, Melo M, Rouleau JL. Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results). *J Am Soc Hypertens*. 2007;1:286-94. [PMID: 20409860]
212. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. *J Hypertens*. 2007;25:951-8. [PMID: 17414657]
213. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA*. 2004;292:2217-25. [PMID: 15536108]
214. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet*. 2003;362:767-71. [PMID: 13678869]
215. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. *Hypertension*. 2006;48:385-91. [PMID: 16864741]
216. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al; Losartan Intervention for Endpoint reduction in hypertension Study Investigators. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. *Circulation*. 2003;108:684-90. [PMID: 12885747]
217. H5N1 avian influenza: first steps towards development of a human vaccine. *Wkly Epidemiol Rec*. 2005;80:277-8. [PMID: 16171030]
218. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, et al; American Heart Association. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. *Circulation*. 2006;114:1549-53. [PMID: 16982936]
219. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. *JAMA*. 1999;281:1927-36. [PMID: 10349897]
220. Ezekowitz MD, Hossack K, Mehta JL, Thadani U, Weidler DJ, Kostuk W, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. *Am Heart J*. 1995;129:527-35. [PMID: 7872184]
221. Boman K, Saetre H, Karlsson LG, Ritter B, Marsell R, Wingman H, et al. Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. *Eur J Clin Pharmacol*. 1995;49:27-30. [PMID: 8751017]
222. Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. *Drugs*. 1996;51:792-819. [PMID: 8861548]
223. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. *N Engl J Med*. 1998;338:520-31. [PMID: 9468470]
224. Böttcher M, Madsen MM, Randsbaek F, Refsgaard J, Dørup I, Sørensen K, et al. Effect of oral nitroglycerin and cold stress on myocardial perfusion in areas subtended by stenosed and nonstenosed coronary arteries. *Am J Cardiol*. 2002;89:1019-24. [PMID: 11988188]
225. Münzel T, Mülsch A, Kleschyov A. Mechanisms underlying nitroglycerin-induced superoxide production in platelets: some insight, more questions [Editorial]. *Circulation*. 2002;106:170-2. [PMID: 12105152]
226. Lacoste LL, Thérault P, Lidón RM, Colucci R, Lam JY. Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. *Am J Cardiol*. 1994;73:1058-62. [PMID: 8198030]
227. Abrams J, Frishman W. *The Organic Nitrates and Nitroprusside*. New York: McGraw-Hill; 2003.
228. Morrow D, Bersh B, Braunwald E. *Chronic Coronary Artery Disease*. Philadelphia: Elsevier Saunders; 2005.
229. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. *JAMA*. 2004;291:309-16. [PMID: 14734593]
230. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. *J Am Coll Cardiol*. 2006;48:566-75. [PMID: 16875985]
231. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al; MARISA Investigators. Anti-ischemic effects and long-term survival during ra-

- nolazine monotherapy in patients with chronic severe angina. *J Am Coll Cardiol*. 2004;43:1375-82. [PMID: 15093870]
232. **Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al; MERLIN-TIMI 36 Trial Investigators.** Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. *JAMA*. 2007;297:1775-83. [PMID: 17456819]
233. **Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al; SYNTAX Investigators.** Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med*. 2009;360:961-72. [PMID: 19228612]
234. **Feit F, Brooks MM, Sopko G, Keller NM, Rosen A, Krone R, et al.** Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. *BARI Investigators. Circulation*. 2000;101:2795-802. [PMID: 10859284]
235. **King SB 3rd, Barnhart HX, Kosinski AS, Weintraub WS, Lembo NJ, Petersen JY, et al.** Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes. *Emory Angioplasty versus Surgery Trial Investigators. Am J Cardiol*. 1997;79:1453-9. [PMID: 9185632]
236. **Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, et al.** Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. *J Am Coll Cardiol*. 2008;51:538-45. [PMID: 18237682]
237. **Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al.** Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. *Lancet*. 1994;344:563-70. [PMID: 7914958]
238. **Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD, et al; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators.** Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. *Am Heart J*. 2001;142:119-26. [PMID: 11431667]
239. **Jones RH, Kesler K, Phillips HR 3rd, Mark DB, Smith PK, Nelson CL, et al.** Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. *J Thorac Cardiovasc Surg*. 1996;111:1013-25. [PMID: 8622299]
240. **Myers WO, Schaff HV, Gersh BJ, Fisher LD, Kosinski AS, Mock MB, et al.** Improved survival of surgically treated patients with triple vessel coronary artery disease and severe angina pectoris. A report from the Coronary Artery Surgery Study (CASS) registry. *J Thorac Cardiovasc Surg*. 1989;97:487-95. [PMID: 2648078]
241. **Varnauskas E.** Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. *N Engl J Med*. 1988;319:332-7. [PMID: 3260659]
242. **Every NR, Fahrenbruch CE, Hallstrom AP, Weaver WD, Cobb LA.** Influence of coronary bypass surgery on subsequent outcome of patients resuscitated from out of hospital cardiac arrest. *J Am Coll Cardiol*. 1992;19:1435-9. [PMID: 1593036]
243. **Holmes DR Jr, Davis K, Gersh BJ, Mock MB, Pettinger MB.** Risk factor profiles of patients with sudden cardiac death and death from other cardiac causes: a report from the Coronary Artery Surgery Study (CASS). *J Am Coll Cardiol*. 1989;13:524-30. [PMID: 2918155]
244. **Tresch DD, Wetherbee JN, Siegel R, Troup PJ, Keelan MH Jr, Olinger GN, et al.** Long-term follow-up of survivors of prehospital sudden cardiac death treated with coronary bypass surgery. *Am Heart J*. 1985;110:1139-45. [PMID: 4072871]
245. **Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al; BARI 2D Study Group.** A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med*. 2009;360:2503-15. [PMID: 19502645]
246. **Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al; STICH Investigators.** Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med*. 2011;364:1607-16. [PMID: 21463150]
247. **Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS.** Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. *Circulation*. 2003;107:2900-7. [PMID: 12771008]
248. **Di Carli MF, Asgarzadeh F, Schelbert HR, Brunken RC, Laks H, Phelps ME, et al.** Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. *Circulation*. 1995;92:3436-44. [PMID: 8521565]
249. **Di Carli MF, Maddahi J, Rokhsar S, Schelbert HR, Bianco-Battles D, Brunken RC, et al.** Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. *J Thorac Cardiovasc Surg*. 1998;116:997-1004. [PMID: 9832692]
250. **Sorajja P, Chareonthaitawee P, Rajagopalan N, Miller TD, Frye RL, Hodge DO, et al.** Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. *Circulation*. 2005;112:1311-6. [PMID: 16159837]
251. **Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al; COURAGE Investigators.** Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. *Circulation*. 2008;117:1283-91. [PMID: 18268144]
252. **Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al; COURAGE Trial Research Group.** Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*. 2007;356:1503-16. [PMID: 17387127]
253. **Cecil WT, Kasteridis P, Barnes JW Jr, Mathis RS, Patric K, Martin S.** A meta-analysis update: percutaneous coronary interventions. *Am J Manag Care*. 2008;14:521-8. [PMID: 18690768]
254. **Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, et al.** Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. *Circulation*. 2004;109:1371-8. [PMID: 15007010]
255. **Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM.** Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. *Lancet*. 2009;373:911-8. [PMID: 19286090]
256. **Katritsis DG, Ioannidis JP.** Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. *Circulation*. 2005;111:2906-12. [PMID: 15927966]
257. **Kern MJ, Donohue TJ, Aguirre FV, Bach RG, Caracciolo EA, Wolford T, et al.** Clinical outcome of deferring angioplasty in patients with normal transluminal pressure-flow velocity measurements. *J Am Coll Cardiol*. 1995;25:178-87. [PMID: 7798498]
258. **Lavi S, Rihal CS, Yang EH, Fassa AA, Elesber A, Lennon RJ, et al.** The effect of drug eluting stents on cardiovascular events in patients with intermediate lesions and borderline fractional flow reserve. *Catheter Cardiovasc Interv*. 2007;70:525-31. [PMID: 17896397]
259. **Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, et al.** Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol*. 2007;49:2105-11. [PMID: 17531660]
260. **O'Connor CM, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, et al.** Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). *Am J Cardiol*. 2002;90:101-7. [PMID: 12106836]
261. **Phillips HR, O'Connor CM, Rogers J.** Revascularization for heart failure. *Am Heart J*. 2007;153:65-73. [PMID: 17394905]
262. **Tarajki KG, Brunken R, McCarthy PM, Al-Chekakie MO, Abdel-Latif A, Pothier CE, et al.** Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. *Circulation*. 2006;113:230-7. [PMID: 16391157]
263. **Tsuyuki RT, Shrive FM, Galbraith PD, Knudtson ML, Graham MM; APPROACH Investigators.** Revascularization in patients with heart failure. *CMAJ*. 2006;175:361-5. [PMID: 16908896]
264. **Sawada S, Bapat A, Vaz D, Weksler J, Fineberg N, Greene A, et al.** Incremental value of myocardial viability for prediction of long-term prognosis in surgically revascularized patients with left ventricular dysfunction. *J Am Coll Cardiol*. 2003;42:2099-105. [PMID: 14680734]

265. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). *Circulation*. 1983;68:785-95. [PMID: 6352078]
266. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. *Ann Intern Med*. 2007;147:703-16. [PMID: 17938385]
267. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. *Am J Cardiol*. 1972;29:154-63. [PMID: 5058341]
268. Sullivan AK, Holdright DR, Wright CA, Sparrow JL, Cunningham D, Fox KM. Chest pain in women: clinical, investigative, and prognostic features. *BMJ*. 1994;308:883-6. [PMID: 8173366]
269. Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. *JAMA*. 2005;293:477-84. [PMID: 15671433]
270. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. *Arch Intern Med*. 2009;169:843-50. [PMID: 19433695]
271. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. *N Engl J Med*. 1999;341:217-25. [PMID: 10413733]
272. Edwards FH, Carey JS, Grover FL, Bero JW, Hartz RS. Impact of gender on coronary bypass operative mortality. *Ann Thorac Surg*. 1998;66:125-31. [PMID: 9692451]
273. Holubkov R, Laskey WK, Haviland A, Slater JC, Bourassa MG, Vlachos HA, et al; NHLBI Dynamic Registry. Registry Investigators. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. *Am Heart J*. 2002;144:826-33. [PMID: 12422151]
274. Vaccarino V, Abramson JL, Veledar E, Weintraub WS. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. *Circulation*. 2002;105:1176-81. [PMID: 11889010]
275. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, et al; Global Registry of Acute Coronary Events investigators. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. *Heart*. 2009;95:20-6. [PMID: 18463200]
276. Moscucci M, Kline-Rogers E, Share D, O'Donnell M, Maxwell-Eward A, Meengs WL, et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. *Circulation*. 2001;104:263-8. [PMID: 11457742]
277. Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. *J Am Coll Cardiol*. 2002;39:1104-12. [PMID: 11923032]
278. Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, et al; ACC-NCDR. Updated risk adjustment mortality model using the complete 1.1 dataset from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). *J Invasive Cardiol*. 2003;15:578-80. [PMID: 14519891]
279. Singh M, Rihal CS, Lennon RJ, Garratt KN, Mathew V, Holmes DR Jr. Prediction of complications following nonemergency percutaneous coronary interventions. *Am J Cardiol*. 2005;96:907-12. [PMID: 16188514]
280. Wu C, Hannan EL, Walford G, Ambrose JA, Holmes DR Jr, King SB 3rd, et al. A risk score to predict in-hospital mortality for percutaneous coronary interventions. *J Am Coll Cardiol*. 2006;47:654-60. [PMID: 16458151]
281. Singh M, Rihal CS, Gersh BJ, Roger VL, Bell MR, Lennon RJ, et al. Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. *J Am Coll Cardiol*. 2008;51:2313-20. [PMID: 18549915]
282. Singh M, Lennon RJ, Holmes DR Jr, Bell MR, Rihal CS. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. *J Am Coll Cardiol*. 2002;40:387-93. [PMID: 12142101]
283. Kwok JM, Miller TD, Hodge DO, Gibbons RJ. Prognostic value of the Duke treadmill score in the elderly. *J Am Coll Cardiol*. 2002;39:1475-81. [PMID: 11985910]
284. Jeger RV, Zellweger MJ, Kaiser C, Grize L, Osswald S, Buser PT, et al; TIME Investigators. Prognostic value of stress testing in patients over 75 years of age with chronic angina. *Chest*. 2004;125:1124-31. [PMID: 15006977]
285. Innocenti F, Totti A, Baroncini C, Fattirolli F, Burgisser C, Pini R. Prognostic value of dobutamine stress echocardiography in octogenarians. *Int J Cardiovasc Imaging*. 2011;27:65-74. [PMID: 20589431]
286. Perrone-Filardi P, Costanzo P, Dellegrottaglie S, Gargiulo P, Ruggiero D, Savarese G, et al. Prognostic role of myocardial single photon emission computed tomography in the elderly. *J Nucl Cardiol*. 2010;17:310-5. [PMID: 20033857]
287. Bouzas-Mosquera A, Peteiro J, Broullón FJ, Álvarez-García N, Méndez E, Pérez A, et al. Value of exercise echocardiography for predicting mortality in elderly patients. *Eur J Clin Invest*. 2010;40:1122-30. [PMID: 20718848]
288. Bernheim AM, Kittipovanonth M, Takahashi PY, Gharacholou SM, Scott CG, Pellikka PA. Does the prognostic value of dobutamine stress echocardiography differ among different age groups? *Am Heart J*. 2011;161:740-5. [PMID: 21473974]
289. Qureshi MA, Safian RD, Grines CL, Goldstein JA, Westveer DC, Glazier S, et al. Simplified scoring system for predicting mortality after percutaneous coronary intervention. *J Am Coll Cardiol*. 2003;42:1890-5. [PMID: 14662247]
290. Resnic FS, Ohno-Machado L, Selwyn A, Simon DI, Popma JJ. Simplified risk score models accurately predict the risk of major in-hospital complications following percutaneous coronary intervention. *Am J Cardiol*. 2001;88:5-9. [PMID: 11423050]
291. Feldman DN, Gade CL, Slotwiner AJ, Parikh M, Bergman G, Wong SC, et al; New York State Angioplasty Registry. Comparison of outcomes of percutaneous coronary interventions in patients of three age groups (<60, 60 to 80, and >80 years) (from the New York State Angioplasty Registry). *Am J Cardiol*. 2006;98:1334-9. [PMID: 17134624]
292. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al; American College of Cardiology. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol*. 2007;50:e1-e157. [PMID: 17692738]
293. Haffner SM. Coronary heart disease in patients with diabetes [Editorial]. *N Engl J Med*. 2000;342:1040-2. [PMID: 10749967]
294. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. *Hypertension*. 2001;37:1053-9. [PMID: 11304502]
295. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet*. 2009;373:1190-7. [PMID: 19303634]
296. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med*. 2004;351:1285-95. [PMID: 15385655]
297. Brosius FC 3rd, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, et al; American Heart Association Kidney and Cardiovascular Disease Council. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. *Circulation*. 2006;114:1083-7. [PMID: 16894032]
298. Matzkies FK, Reinecke H, Regetteimer A, Breithardt G, Kerber S, Hohage H, et al. Long-term outcome after percutaneous transluminal coronary angioplasty in patients with chronic renal failure with and without diabetic nephropathy. *Nephron*. 2001;89:10-4. [PMID: 11528225]
299. Sedlis SP, Jurkovic CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, et al; COURAGE Study Investigators. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. *Am J Cardiol*. 2009;104:1647-53. [PMID: 19962469]

300. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol*. 2004;44:1393-9. [PMID: 15464318]
301. Goel K, Thomas RJ, Squires RW, Coutinho T, Trejo-Gutierrez JF, Somers VK, et al. Combined effect of cardiorespiratory fitness and adiposity on mortality in patients with coronary artery disease. *Am Heart J*. 2011;161:590-7. [PMID: 21392616]
302. Goyal D, Logie IM, Nadar SK, Lip GY, Macfadyen RJ. Generalized obesity but not that characterized by raised waist-hip ratio is associated with increased perceived breathlessness during treadmill exercise testing. *Cardiovasc Ther*. 2009;27:10-6. [PMID: 19207475]
303. McNulty PH, Ettinger SM, Field JM, Gilchrist IC, Kozak M, Chambers CE, et al. Cardiac catheterization in morbidly obese patients. *Catheter Cardiovasc Interv*. 2002;56:174-7. [PMID: 12112908]
304. Pazhenkottil AP, Ghadri JR, Nkoulou RN, Wolftrum M, Buechel RR, Küest SM, et al. Improved outcome prediction by SPECT myocardial perfusion imaging after CT attenuation correction. *J Nucl Med*. 2011;52:196-200. [PMID: 21270455]
305. Duvall WL, Croft LB, Corriel JS, Einstein AJ, Fisher JE, Haynes PS, et al. SPECT myocardial perfusion imaging in morbidly obese patients: image quality, hemodynamic response to pharmacologic stress, and diagnostic and prognostic value. *J Nucl Cardiol*. 2006;13:202-9. [PMID: 16580956]
306. Berman DS, Kang X, Nishina H, Slomka PJ, Shaw LJ, Hayes SW, et al. Diagnostic accuracy of gated Tc-99m sestamibi stress myocardial perfusion SPECT with combined supine and prone acquisitions to detect coronary artery disease in obese and nonobese patients. *J Nucl Cardiol*. 2006;13:191-201. [PMID: 16580955]
307. Slomka PJ, Nishina H, Abidov A, Hayes SW, Friedman JD, Berman DS, et al. Combined quantitative supine-prone myocardial perfusion SPECT improves detection of coronary artery disease and normalcy rates in women. *J Nucl Cardiol*. 2007;14:44-52. [PMID: 17276305]
308. Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S, Miller JG, et al. Contrast echocardiography: current and future applications. *J Am Soc Echocardiogr*. 2000;13:331-42. [PMID: 10756254]
309. Mehta NJ, Khan IA. HIV-associated coronary artery disease. *Angiology*. 2003;54:269-75. [PMID: 12785019]
310. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. *Coron Artery Dis*. 2000;11:41-6. [PMID: 10715805]
311. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. *Arch Intern Med*. 2003;163:457-60. [PMID: 12588205]
312. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al; Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. *Arch Intern Med*. 2010;170:1228-38. [PMID: 20660842]
313. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect Dis*. 2010;201:318-30. [PMID: 20039804]
314. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. *N Engl J Med*. 2003;348:702-10. [PMID: 12594314]
315. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al; DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med*. 2007;356:1723-35. [PMID: 17460226]
316. Khunnawat C, Mukerji S, Havlichek D Jr, Touma R, Abela GS. Cardiovascular manifestations in human immunodeficiency virus-infected patients. *Am J Cardiol*. 2008;102:635-42. [PMID: 18721528]
317. Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. *J Rheumatol*. 2007;34:937-42. [PMID: 17361987]
318. Avendano M, Kunst AE, Huisman M, Lenthe FV, Bopp M, Regidor E, et al. Socioeconomic status and ischaemic heart disease mortality in 10 western European populations during the 1990s. *Heart*. 2006;92:461-7. [PMID: 16216862]
319. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. *Nat Rev Cardiol*. 2009;6:712-22. [PMID: 19770848]
320. Alter DA, Iron K, Austin PC, Naylor CD; SESAMI Study Group. Socioeconomic status, service patterns, and perceptions of care among survivors of acute myocardial infarction in Canada. *JAMA*. 2004;291:1100-7. [PMID: 14996779]
321. Davis AM, Vinci LM, Okwuosa TM, Chase AR, Huang ES. Cardiovascular health disparities: a systematic review of health care interventions. *Med Care Res Rev*. 2007;64:29S-100S. [PMID: 17881625]
322. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA*. 2001;286:180-7. [PMID: 11448281]
323. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med*. 1979;300:1350-8. [PMID: 440357]
324. Clayton TC, Lubsen J, Pocock SJ, Vokó Z, Kirwan BA, Fox KA, et al. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. *BMJ*. 2005;331:869. [PMID: 16210253]
325. Daly CA, De Stavola B, Sendon JL, Tavazzi L, Boersma E, Clemens F, et al; Euro Heart Survey Investigators. Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study. *BMJ*. 2006;332:262-7. [PMID: 16415069]
326. Daly C, Norrie J, Murdoch DL, Ford I, Dargie HJ, Fox K; TIBET (Total Ischaemic Burden European Trial) study group. The value of routine non-invasive tests to predict clinical outcome in stable angina. *Eur Heart J*. 2003;24:532-40. [PMID: 12643886]
327. Poole-Wilson PA, Vokó Z, Kirwan BA, de Brouwer S, Dunselman PH, Lubsen J; ACTION investigators. Clinical course of isolated stable angina due to coronary heart disease. *Eur Heart J*. 2007;28:1928-35. [PMID: 17562665]
328. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. *Lancet*. 2002;359:1269-75. [PMID: 11965271]
329. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, et al; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. *J Am Coll Cardiol*. 2003;42:1161-70. [PMID: 14522473]
330. Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, et al; Trial of Invasive versus Medical therapy in Elderly patients (TIME) Investigators. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. *JAMA*. 2003;289:1117-23. [PMID: 12622581]
331. Gianrossi R, Detrano R, Mulvihill D, Lehmann K, Dubach P, Colombo A, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. *Circulation*. 1989;80:87-98. [PMID: 2661056]
332. Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. *JAMA*. 1998;280:913-20. [PMID: 9739977]
333. Hachamovitch R, Hayes S, Friedman JD, Cohen I, Shaw LJ, Germano G, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? *J Am Coll Cardiol*. 2003;41:1329-40. [PMID: 12706929]

Current Author Addresses: Dr. Qaseem: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.
Dr. Fihn: 1100 Olive Way, Seattle, WA 98101.
Dr. Dallas: 1906 Bellview Avenue, Roanoke, VA 24014.
Dr. Williams: 423 Guardian Drive, Philadelphia, PA 19104.
Dr. Owens: 117 Encina Commons, Stanford, CA 94305.
Dr. Shekelle: 11301 Wiltshire Boulevard, Los Angeles, CA 90073.

Author Contributions: Conception and design: A. Qaseem, S.D. Fihn, D.K. Owens, P. Shekelle.

Analysis and interpretation of the data: A. Qaseem, S.D. Fihn, P. Dallas, S. Williams, D.K. Owens.

Drafting of the article: A. Qaseem, P. Dallas, S. Williams, D.K. Owens.

Critical revision of the article for important intellectual content: A. Qaseem, S.D. Fihn, P. Dallas, S. Williams, D.K. Owens, P. Shekelle.

Final approval of the article: A. Qaseem, S.D. Fihn, S. Williams, D.K. Owens, P. Shekelle.

Statistical expertise: A. Qaseem.

Administrative, technical, or logistic support: A. Qaseem.

Collection and assembly of data: A. Qaseem, S.D. Fihn.